National Pricing Model 2024–25

For Australian public hospital services

Technical Specifications

March 2024

National Pricing Model 2024–25 – Technical Specifications – March 2024

© Independent Health and Aged Care Pricing Authority 2024

This publication is available for your use under a [Creative Commons BY Attribution 3.0 Australia](http://creativecommons.org/licenses/by/3.0/au/deed.en) licence, with the exception of the Independent Health and Aged Care Pricing Authority logo, photographs, images, signatures and where otherwise stated. The full licence terms are available from [the Creative Commons website](http://creativecommons.org/licenses/by/3.0/au/legalcode).



Use of Independent Health and Aged Care Pricing Authority material under a [Creative Commons BY Attribution 3.0 Australia](http://creativecommons.org/licenses/by/3.0/au/deed.en) licence requires you to attribute the work (but not in any way that suggests that the Independent Health and Aged Care Pricing Authority endorses you or your use of the work).

*Independent Health and Aged Care Pricing Authority material used 'as supplied'.*

Provided you have not modified or transformed Independent Health and Aged Care Pricing Authority material in any way including, for example, by changing Independent Health and Aged Care Pricing Authority text – then the Independent Health and Aged Care Pricing Authority prefers the following attribution:

*Source: The Independent Health and Aged Care Pricing Authority*

# Contents

[Table of acronyms and abbreviations 3](#_Toc161749797)

[1. Overview 5](#_Toc161749798)

[1.1 Purpose 5](#_Toc161749799)

[1.2 Background 5](#_Toc161749800)

[1.3 National efficient price 2024–25 process 5](#_Toc161749801)

[2. Admitted acute care cost model 8](#_Toc161749802)

[2.1 General issues 8](#_Toc161749803)

[2.2 Analysis of costs to derive NWAU for admitted acute care 9](#_Toc161749804)

[2.3 Applying the NEP 21](#_Toc161749805)

[3. Mental health care cost model 24](#_Toc161749806)

[3.1 General issues 24](#_Toc161749807)

[3.2 Analysis of costs to derive NWAU for mental health care 24](#_Toc161749808)

[4. Admitted subacute and non‑acute care cost model 32](#_Toc161749809)

[4.1 General issues 32](#_Toc161749810)

[4.2 Analysis of costs to derive NWAU for subacute and non-acute admitted care 32](#_Toc161749811)

[5. Emergency care cost model 38](#_Toc161749812)

[5.1 General issues 38](#_Toc161749813)

[5.2 Analysis of costs to derive NWAU for emergency care 38](#_Toc161749814)

[6. Non-admitted care cost model 41](#_Toc161749815)

[6.1 Overview 41](#_Toc161749816)

[6.2 Analysis of costs to derive NWAU for non-admitted care 41](#_Toc161749817)

[7. Conversion to a pricing model 47](#_Toc161749818)

[7.1 Overview 47](#_Toc161749819)

[7.2 Identification of out-of-scope costs 48](#_Toc161749820)

[7.3 Derivation of a reference cost 49](#_Toc161749821)

[7.4 Indexation 50](#_Toc161749822)

[7.5 Transformation of cost model to pricing model 55](#_Toc161749823)

[7.6 Back-casting for ABF 56](#_Toc161749824)

[8. Block-funded hospitals 58](#_Toc161749825)

[8.1 General issues 58](#_Toc161749826)

[8.2 Analysis of costs 59](#_Toc161749827)

[8.3 Calculation of national efficient cost 62](#_Toc161749828)

[8.4 Indexation of the 2021–22 model 63](#_Toc161749829)

[8.5 Back-casting for block-funded hospitals 64](#_Toc161749830)

[Appendices 65](#_Toc161749831)

[Appendix A: Reference tables 66](#_Toc161749832)

[Appendix B: Application of NWAU variables 68](#_Toc161749833)

[Appendix C: Summary of input data 82](#_Toc161749834)

[Appendix D: List of AR-DRGs adopting the L1.5 H1.5 methodology 84](#_Toc161749835)

[Appendix E: NEC24 data preparation 85](#_Toc161749836)

# Table of acronyms and abbreviations

**Acronym/ abbreviation Description**

|  |  |
| --- | --- |
| ABF | Activity based funding |
| ABS | Australian Bureau of Statistics |
| AECC | Australian emergency care classification |
| AHR | Avoidable hospital readmission |
| ALOS | Average length of stay |
| AMHCC | Australian mental health care classification |
| AN-SNAP | Australian national subacute and non-acute patient classification |
| APC | Admitted patient care |
| APCP | Admitted patient cost proportion |
| AR‐DRG | Australian refined diagnosis related group |
| ASGS | Australian statistical geography standard |
| ASNC | Admitted subacute and non-acute care |
| COAG | Council of Australian Governments |
| DSS | Data set specification |
| ED | Emergency department |
| HAC | Hospital acquired complication |
| HCP | Hospital casemix protocol |
| ICU | Intensive care unit |
| IHACPA | Independent Health and Aged Care Pricing Authority |
| LHN | Local hospital network |
| LOS | Length of stay |
| MAPE | Mean absolute percentage error |
| MBS | Medicare benefits schedule |
| MDC | Major diagnostic category, used in AR-DRGs |
| MHC | Mental health care |
| MPS | Multi-purpose service |
| NAPED | Non-admitted patients emergency department |
| NBEDS | National best endeavours data set |
| NEC | National efficient cost |
| NEP | National efficient price |
| NHCDC | National hospital cost data collection |
| NHRA | National Health Reform Agreement |
| NMC | Non-admitted multi-disciplinary clinic |
| NMDS | National minimum data set |
| NPHED | National public hospital establishment database |
| NWAU | National weighted activity unit |
| OTA | Organ and Tissue Authority |
| PICU | Paediatric intensive care unit |
| SA2 | Statistical areas level 2 |
| TTR | Teaching, training and research |
| UDG | Urgency disposition groups |
| WAU | Weighted activity unit |

# 1. Overview

## 1.1 Purpose

This document has been produced as an accompaniment to the National Efficient Price Determination 2024–25 (NEP24) and the National Efficient Cost Determination 2024–25 (NEC24). It provides the technical specifications for how the Independent Health and Aged Care Pricing Authority (IHACPA) developed the activity based funding (ABF) models for the service streams to be funded on this basis from 1 July 2024, and provides guidance to hospitals, local hospital networks (LHN), and state and territory health authorities on how to apply these to hospital activity. It also shows how the national efficient cost (NEC) is determined for hospitals (such as small rural hospitals) funded on a block funded basis.

## 1.2 Background

The National Health Reform Agreement (NHRA) and its 2020–25 Addendum set out the intention of the Australian Government, and state and territory governments to work in partnership to improve health outcomes for all Australians. One of the ways in which the NHRA aims to achieve this is through the implementation of national ABF funding arrangements. The NHRA specifies that the central component of ABF is an independently determined NEP and NEC, to be used as a reference for the Commonwealth to determine its funding contribution for Australian public hospital services.

IHACPA is a key element of the NHRA, responsible for the national implementation of an ABF system and in determining the annual NEP and NEC for Australian public hospital services. IHACPA was established as an independent government agency under Commonwealth legislation on 15 December 2011. It has issued twelve NEP Determinations annually since 2012–‍13 (NEP12) and eleven NEC Determinations since 2013–14 (NEC13).


The published NEP and NEC, sets out the determinations for 2024–25 in relation to each of IHACPA’s legislative functions, namely:

* The NEP for health care services provided by public hospitals where the services are funded on an activity basis.
* The NEC for health care services provided by public hospitals where the services are funded on a block funded basis.
* The development and specification of classification systems for health care and other services provided by public hospitals.
* Adjustments to the NEP to reflect legitimate and unavoidable variations in the costs of delivering health care services.
* Except where otherwise agreed between the Commonwealth and a state or a territory — to determine the public hospital functions that are to be part-funded in that state or territory by the Commonwealth.
* Publication of a report setting out the NEP and NEC for the coming year and any other information that would support the efficient funding of public hospitals.

## 1.3 National efficient price 2024–25 process

The figure below outlines the NEP24 process from development of classification systems to publishing the NEP and NEC Determinations for 2024–25.

**Figure 1: Process to determine the national efficient price 2024–25**



### 1.3.1 Classification systems

One of the first stages is to classify hospital activity under various systems dependent on the ABF service stream. IHACPA has collated activity and cost data for each of the ABF service streams to be funded on an activity basis in 2024–25, as follows:

* Admitted acute
* Admitted mental health care
* Admitted subacute and non-acute
* Emergency care
* Non-admitted care.

Classification systems within each service stream are applied uniformly across all available data. Although these systems are developed in part to explain variation in cost between different outputs within the stream, additional systematic variation still occurs. To account for this, various adjustments are modelled and where justified, implemented into the models. The classification systems for each service stream and the source of its cost and activity data are outlined in **Appendix A**: Reference tables.

### 1.3.2 Data preparation

An important part of the modelling process is the preliminary preparation of both the costing and activity data. The essential steps in the data preparation process are:

1. A substantial validation process undertaken as the data are received from jurisdictions.
2. Linking the National Hospital Cost Data Collection (NHCDC) cost file with the admitted patient care activity file at the patient level (which has recorded a success rate of approximately 96 per cent).
3. Matching mothers with unqualified neonates[[1]](#footnote-2) to ensure costs are properly attributed to the mothers.
4. Identifying any differences in patient characteristics or operational data recorded across the two data sets and reconciling these where appropriate.
5. Where reported, removing blood costs and/or any identified amounts related to Commonwealth pharmaceutical payments.

The activity and cost data is sourced by IHACPA from various national data collections and is supplemented by additional data provided by the states and territories. In consultation with jurisdictions, IHACPA has identified 425 hospitals to make up the ABF price model and 388 hospitals designated for block funding. Of the block-funded hospitals:

* 14 are being treated separately as specialist mental health establishments.
* Nine are major city hospitals.
* One which does not fit the cost model structure.
* 364 hospitals comprise the block-funded cost model.[[2]](#footnote-3)

**Appendix C**: Summary of input data provides a summary of the NHCDC Round 26 cost data received for 2021–22.

The next stage in the process is to develop the 2021–22 cost models. This process includes deriving the cost profiles, adjustments and relative weights of classes within each service stream. Development of the individual cost models are explained in further detail in the corresponding sections of this document.

### 1.3.3 Conversion to a pricing model

There are four steps in the transformation of each year’s cost model into its associated pricing model, namely:

1. Identification and exclusion of costs and activity regarded under the NHRA as out-of-scope for the purpose of ABF.
2. Derivation of a reference cost (or standardised mean) used to transform the cost model into a cost weight model.
3. Derivation of an annual indexation rate used to inflate the cost model to a level reflective of the estimated cost of delivering hospital services in the year of the pricing model.
4. Transformation of the cost model to the pricing model using the results of the previous three steps.

This is explained in further detail in Section 7.

# 2. Admitted acute care cost model

## 2.1 General issues

### 2.1.1 Cost unit

An ‘episode of admitted patient care’ is the cost unit for admitted acute patients. It is ‘the period of admitted patient care… characterised by only one care type’, and covers the period of care from admission to separation [see Australian Institute of Health and Welfare’s Metadata Online Registry (METeOR) identifier 268956].

### 2.1.2 In-scope activity

There are three care types used to inform the admitted acute cost model[[3]](#footnote-4):

* Acute care
* Newborn care
* other forms of admitted patient care used to supplement data.

All episodes from all funding sources are included in the calculation of the cost weights. This approach is taken to ensure that the sample used for the development of national weighted activity unit (NWAU) is maximised and reflects the overall costs for the hospital. Only in-scope admitted acute episodes and associated relevant costs are included in the calculation of the NEP, as described in Section 7.

**In-scope costs**

Factors impacting scope of costs include:

* Costs associated with the admitted episode where a patient is admitted through an emergency department that is within the scope of ABF for emergency care. This component of cost is separated from the acute episode and funded through the emergency care funding model.
* Depreciation and other capital costs (including leases) where reported, are removed.
* Indirect costs for teaching, training and research (TTR) are included, but any direct TTR costs are excluded.
* Identified blood costs and Commonwealth pharmaceutical payments are removed.

### 2.1.3 Classification

Australian Refined Diagnosis Related Groups (AR-DRGs) are used to classify admitted acute care. The version applied for pricing in 2024–25 is AR-DRG Version 11.0.

## 2.2 Analysis of costs to derive NWAU for admitted acute care

This section provides an overview of the steps involved in developing the NWAU for admitted acute care. Detailed information in relation to each of the components of the model is included below. In summary, the steps involved in developing the NWAU for admitted acute care are:

1. Prepare data, including the removal of other Commonwealth expenditure (in particular the pharmaceutical and blood programs).
2. Incorporate posthumous organ donation activity costs.
3. Incorporate private patient costs from hospital casemix protocol (HCP) data where there is evidence they have not been provided as part of the NHCDC.
4. Stratify and weight cost data to activity data.
5. Calculate inlier bounds from activity data.
6. Classify episodes into relevant categories including inliers, short-stay and long-stay outliers, designated same-day AR-DRGs, paediatric status, Indigenous status and remoteness area status, receiving COVID-19 treatment and establishments reporting radiotherapy procedures.
7. Determine cost level for intensive care unit (ICU) adjustment and deduct associated costs.
8. Derive initial parameters for AR-DRG inlier/outlier model and ensure predicted costs align with actual costs by AR-DRG.
9. Derive paediatric adjustment, Indigenous adjustment, remoteness adjustment, radiotherapy adjustment and dialysis adjustment.
10. Derive COVID-19 treatment adjustment.
11. Derive private patient service adjustment and private patient accommodation adjustment.
12. Incorporate data trimmed in data preparation process (outlier samples of cost data).
13. Convert price weights and assign NWAU.
14. Apply stabilisation of acute weights.

These steps are described in further detail in the following sections.

### 2.2.1 Data preparation

The 2021–22 NHCDC data is first adjusted to remove those costs associated with spending under other Commonwealth programs. Costs associated with the Commonwealth’s pharmaceutical programs are identified by matching the NHCDC at the patient level with a record of the Commonwealth pharmaceutical payments. The residual unmatched payments are apportioned according to the distribution of costs associated with the matched records. All reported blood costs are removed from the NHCDC. The amounts deducted from the reported costs are identified in Chapter 2 of the National Efficient Price Determination 2024–25.

Table 1 shows the trimming stages and the number of episodes trimmed at each stage of the data preparation process.

Table 1: Number of episodes trimmed at each data preparation stage

| **Trimming stage** | | **Episodes** |
| --- | --- | --- |
| (a) Initial activity-level cost sample of admitted acute records | | **6,127,591** |
| **Less** – Total trimmed episodes | | **-63,086** |
|  | (b) Patient level cost data trimmed under jurisdictional advice | **-26,096** |
| (c) Episodes from hospital-DRG combinations with extremely high or low cost-to-price ratios | **-11,105** |
| (d) Removal of records with total in-scope costs ≤ $23 | **-25,070** |
| (e) Observations with extreme outlier costs | **-115** |
| (f) Extremely high or low cost ratios removed after deriving the preliminary regression model | **-683** |
| (g) Multi-day AR-DRG R63Z episodes | **-17** |
| (h) Resulting sample size of separations used to create AR-DRG cost profiles | | **6,064,505** |

For the financial year 2021–22:

1. An activity-level cost sample of 6,127,591 admitted acute records (with both the admission and separation dates within this period) were partitioned into two groups for modelling purposes. The first group is evaluated as fit for use to develop AR-DRG cost profiles for the 2021–22 cost model, and a second group identified as not fit for this purpose. The second group is later incorporated into the cost model to calibrate the overall level of costs within the model.
2. 26,096 episodes of patient level cost data was removed from the sample based on jurisdictional advice. A preliminary model with length of stay and DRG as explanatory variables of patient cost was derived and applied to the remaining sample.
3. Episodes from 616 hospital-DRG combinations with extremely high or low cost-to-price ratios were also excluded from the patient level modelling.
4. The sample was further reduced by 25,070 episodes as a result of removing records with total in-scope costs of $23 or less.
5. The remaining sample was then analysed by AR-DRG, and observations with extreme outlier costs were identified and removed. This was done by ranking observations by cost and identifying those values that recorded an extreme increase in cost of over 200 per cent (or a decrease in cost of over 75 per cent) from the previous observation. In total, 115 records were removed at this stage.
6. The extreme outlier identification stage was undertaken by first deriving a preliminary regression model using length of stay and DRG, and analysing the resulting cost ratios. Following this, another 683 individual records with extremely high or low cost ratios were removed.
7. In this final stage, multi-day chemotherapy AR-DRG R63Z episodes were trimmed out. The Australian Coding Standards state that the principal diagnosis code Z51.1 – Pharmacotherapy session for neoplasm which informs DRG of R63Z may only be assigned to same-day episodes. The 17 multi-day episodes with this code were trimmed from the cost model.
8. The resulting sample of 6,064,505 separations were identified for use in creating AR‑DRG cost profiles.

### 2.2.2 Posthumous organ donation activity costs

Posthumous organ donation activity was accounted for in the NEP for the first time in NEP16. This followed advice from the Organ and Tissue Authority (OTA) that funding provided from the OTA to jurisdictions contributes towards the cost of preparing a patient for organ donation, but not for all costs incurred thereafter. This advice from the OTA means that some of the costs of posthumous organ donation are not funded by the Commonwealth and should be in-scope for pricing under the NHRA. This has not changed for NEP24.

IHACPA takes the costs reported against donors in ‘care type 9’ and redistributes these costs to recipient transplant AR-DRGs in the admitted acute model. The total cost associated with each organ procurement is accounted for by inflating the in-scope cost of patients in AR-DRGs, which typically involves the transplant of relevant organs. Note there is no mechanism to link donors with recipients or to gauge the outcome of a procurement or transplant.

The total cost reported against posthumous organ donors in 2021–22 is $4,564,290. This results in a national cost inflation in the admitted acute stream of 0.013 per cent.

### 2.2.3 Private patient costs

Private patient episodes in-scope for ABF include those episodes occurring in a public hospital with a funding source of either ‘09 Private health insurance’ or ‘13 self-funded’ in the 2021–22 Admitted Patient Care (APC) data sets. The NHRA requires that in setting NEP24, IHACPA must take into account the costs of private patients that are met through alternative funding sources. These alternative sources include medical benefits payments by the Australian Government, private health insurance benefits payments, and payments made by patients.

Since NEP14, the HCP dataset, which is reported by private insurance companies, has been used to identify these costs. HCP data identifies both the charges and benefits paid for private patients receiving public hospital services. For NEP24, the private patient records in the HCP dataset were matched with the records in the APC and NHCDC datasets, resulting in a sample of 77.4 per cent match of relevant records. Those private patient records in the NHCDC that were not matched to the HCP data were assumed to have similar characteristics to the matched dataset.

In using the HCP data, a more accurate estimate can be made for the amount of private patient costs not included in the NHCDC data and need a correction factor applied. A correction factor of 1.0 per cent was determined for NEP24.

### 2.2.4 Stratification and weighting

The sample of costed activity from ABF establishments make up 96.1 per cent of all in-scope admitted acute activity (population). To take account of the un-costed activity, IHACPA weights the costed sample to the population. Weighting of the costed sample is applied to ensure a true representation of the entire population. This weighting process is performed in two stages, as outlined below.

**Stage 1 (episodes admitted on or after 1 July 2020 and separated on or before 30 June 2022)**

The first stage of the weighting process stratified and weighted the ABF sample to reflect the population of all 2021–22 ABF admitted acute activity with an admission date *on or after* 1 July 2020. The stratification is based on establishment state/territory, size, location and paediatric specialty. Establishments are classified by size using 2023–24 admitted acute NWAU, calculated on 2021–22 activity data (that is, NWAU23 calculator applied to 2021–22 data).

**Stage 2 (episodes admitted prior to 1 July 2020)**

The second stage of the weighting process weights the 2021–22 activity with an admission date *prior* to 1 July 2020, up to all activity with separation dates within 2020–22. This weighting is done by length of stay quartiles within the AR-DRG. Same-day activity received a weight of 1.0 in this process, as there are no 2021–22 same-day separations with admission dates prior to 1 July 2021.

The resulting sample-to-population weights were used throughout all stages of the cost model development.

### 2.2.5 Inlier bounds

Admitted episodes with length of stay between one-third and three times the average length of stay for a particular AR-DRG are classed as inliers. This methodology is referred to as L3H3, and results in the vast majority of admitted episodes being classed as inliers.

The L3H3 method is applied to the population of in-scope activity from ABF establishments to identify inlier bounds outside of which are short-stay and long-stay outliers. This is illustrated in Figure 2. The method excludes same-day episodes occurring in AR-DRGs designated for a separate same-day payment, and uses length of stay adjusted to remove ICU days for ICU unbundled AR-DRGs.

**Figure 2: Inlier bound calculations**



The L1.5H1.5 method is used for 21 AR-DRGs that have very high cost long-stay outliers. The list of 21 AR-DRGs where the L1.5H1.5 method is used to determine the inlier bounds is provided in **Appendix D**: List of AR-DRGs adopting the L1.5 H1.5 methodology.

The steps for this process are:

1. Calculate the national average length of stay for each AR-DRG.
2. Calculate the inlier lower bound for each AR-DRG. This is based on the calculation: national average length of stay divided by three (1.5 for the 21 specified AR-DRGs). The inlier lower bound is equal to average length of stay divided by three.
3. The result is then truncated. This means that it is rounded down to the next lowest integer (for example, if the result was 3.6, the inlier lower bound is set to three).
4. Calculate the inlier upper bound for each AR-DRG. This is based on the calculation: national average length of stay multiplied by three (1.5 for the 21 specified AR-DRGs).
5. The result was rounded to the nearest integer (for example, 10.2 would result in the upper bound being set to 10, whereas 10.7 would result in the upper bound being set to 11).
6. Episodes with an ICU adjusted length of stay equal to or between the two inlier bounds of the AR‑DRG are considered inlier episodes.

Further to the above process, changes to the inlier bounds from the 2021–22 cost model are monitored to ensure they are the result of real change and not due to ‘statistical noise’. To evaluate whether a change to an AR-DRG is considered significant or not, 95 per cent confidence intervals around bounds are used. Changes are also evaluated in terms of their materiality (required to affect at least one per cent of an AR-DRG’s separations and at least 10 separations). If the average length of stay of a particular end-class falls outside the inlier lower and upper bounds, then the changes in bounds will be implemented even if they do not meet the stability and materiality considerations above.

### 2.2.6 Classification of patient-level cost data in relevant categories

Prior to analysing costs, episodes are assigned to categories reflecting the relevant adjustments to be made through the 2021–22 cost model. The steps involved are:

1. Assigning one of the following categories to each episode:
   * same-day separation from an AR-DRG on the designated same-day payment list
   * short-stay outlier
   * inlier
   * long-stay outlier.
2. Flagging episodes that are eligible for the paediatric adjustment*.* These are episodes that:
   * Occur in establishments identified as delivering specialised paediatric services (listed in **Appendix E** of the National Efficient Price Determination 2024–25).
   * Have an AR-DRG which is not within MDC 15 (newborns and other neonates).
   * Have patient age at admission of 17 years or less.
3. Flagging episodes that are eligible for the Indigenous adjustment.These are episodes with Indigenous status[[4]](#footnote-5) of Aboriginal and/or Torres Strait Islander origin.
4. Flagging episodes that are eligible for the patient residential remoteness adjustment. These are episodes where the patient’s place of usual residencehas been assigned to a remoteness area[[5]](#footnote-6) of:
   * RA2 – outer regional Australia
   * RA3 – remote Australia
   * RA4 – very remote Australia.

Three flags are used: one for outer regional Australia, one for remote Australia and one for very remote Australia. The remoteness area of a patient’s usual residence is determined using the following process:

* + 1. The patient’s Australian Statistical Geography Standard (ASGS) Statistical Areas Level 2 (SA2) code is mapped to remoteness area.
    2. If the supplied SA2 code is missing or invalid, the patient’s postcode of usual residence is used.
    3. If the postcode is missing or invalid, then the remoteness area of the hospital is used. The remoteness code of the hospital is based on the remoteness area of the Australian Bureau of Statistics (ABS) collection district within which the hospital is located.

1. Flagging episodes that are eligible for the radiotherapy adjustment. These are episodes where the patient is eligible if they have recorded a radiotherapy-related procedure as defined in **Appendix B** of the National Efficient Price Determination 2024–25.
2. Flagging episodes that are eligible for the dialysis adjustment*.* These are episodes outside the specified dialysis AR-DRGs L61Z and L68Z, and have recorded a dialysis-related procedure as defined in **Appendix C** of the National Efficient Price Determination 2024–25.
3. Flagging episodes that are eligible for the patient treatment remoteness adjustment.These are episodes where the hospital of treatment has a remoteness area of:
   * RA3 – remote Australia
   * RA4 – very remote Australia.
4. Flagging episodes that are eligible for the COVID-19 treatment adjustment. The first criteria are that in 2021–22 data, used in developing NEP24, these were episodes with diagnosis codes no B34.2 and U07.1 or U07.2 under ICD-10-AM 11th edition. For 2024–25, under ICD-10-AM 12th edition, U07.12 and U07.2 apply instead. The second criterion is that the episodes have an AR-DRG that is listed in **Appendix P** of the National Efficient Price Determination 2024–25.
5. Flagging episodes eligible for the ICU adjustment. These are episodes that occur in hospitals identified by IHACPA as eligible for ICU adjustment as defined in **Appendix D** of the National Efficient Price Determination 2024–25 and have an AR-DRG not on the bundled ICU list (that is, not from MDC 15 for newborns and other neonates).
6. Flagging private episodes.These are episodes with a funding source[[6]](#footnote-7) of ’09 Private health insurance’ or ‘13 Self-funded’.
7. Flagging hospital acquired complications(HACs) and avoidable hospital readmissions (AHRs). These are episodes that are identified as having a HAC and/or an AHR as specified by the Australian Commission on Safety and Quality in Health Care (ACSQHC) on their [website](https://www.safetyandquality.gov.au/our-work/indicators/hospital-acquired-complications/).

### 2.2.7 Determine ICU adjustment level and deduct associated costs

Patient-level cost data for episodes in hospitals with an eligible ICU or paediatric ICU (PICU) with ICU hours reported are analysed to estimate an average cost per ICU hour. The eligible ICUs and PICUs are those belonging to hospitals that report more than 24,000 ICU hours and have more than 20 per cent of those hours reported with the use of mechanical ventilation. The specified hospitals with eligible ICUs and/or PICUs are listed at **Appendix D** of the National Efficient Price Determination 2024–25*.* A total sample of 86,919 separations with ICU hours and costs from establishments with eligible ICUs/PICUs were used. For COVID-19 patients (flagged as per **Appendix B** in the variable row labelled A0), ICU hours in non-specified hospitals will be considered eligible.


Linear regression by state/territory was used to derive state/territory hourly ICU costs. Difference in Fits (DFFITS) statistics are used to exclude overly influential observations. The weighted mean of the hourly ICU costs taken across states was used to derive a national ICU rate of $250 per hour.

For ICU-eligible episodes, an ICU adjustment is calculated using the estimated ICU cost per hour and the reported number of whole ICU hours. This amount is deducted from the in-scope costs used for modelling the same-day payment AR-DRG, short-stay outlier, inlier and long-stay outlier costs and associated adjustments, but added back in for the ICU adjustment. Whole ICU days are also removed from each eligible episode’s length of stay.

### 2.2.8 AR-DRG inlier/outlier model

Figure 3 illustrates the general form of the cost model within each AR-DRG. However, an AR‑DRG’s form may differ depending on whether it has a designated same-day separation category, a short-stay outlier category, or a long-stay outlier category.

**Figure 3: Initial parameters for the assignment of cost weights**



Initial parameters are derived for designated same-day payment AR-DRG episodes, short-stay outlier episodes, inlier episodes, and long-stay outlier episodes. The steps involved are as follows:

1. Designated same-day AR-DRG episodes:calculate the mean cost per episode.
2. Inlier episodes: calculate the mean cost per episode.
3. Short-stay outlier episodes: calculate the base cost as the average of total operating room, special procedure suites and prosthesis costs, and then calculate the cost per diem to ensure an even growth in cost to that of the inlier episode.
4. Long-stay outlier episodes: the mean inlier cost is assigned to each episode as a base amount. A per diem for each outlier day is calculated using one of two methods:
   * In AR-DRGs where the length of stay profile is adequately wide enough and regular to allow robust regression analysis to be undertaken, the per diem cost is taken as the LOS regression coefficient; this process excludes designated same-day episodes and overly influential observations (as determined by the DFFITS statistical measure).
   * In the remaining AR-DRGs, cost buckets are partitioned into ‘fixed’ and ‘variable’ (similar to the short-stay outlier process for surgical AR-DRGs), and the per diem cost is taken as the mean variable cost per patient day.

Where there are fewer than 100 separations in an AR-DRG, 2021–22 separations are combined with those from 2020–21, and indexed appropriately to calculate the cost parameter. All AR-DRG parameters are then uniformly calibrated to ensure the modelled costs are equalised against actual costs.

### 2.2.9 Calculation of additional adjustments

After the AR-DRG inlier/outlier model is derived, the following six sets of adjustments are calculated based on factors considered to have a material impact on the cost of acute services.

**Paediatric adjustment**

A paediatric adjustment is derived by AR-DRG. Specialised paediatric patients are identified as being less than or equal to 17 years of age, from an establishment identified as delivering specialised paediatric services (listed in **Appendix E** of the National Efficient Price Determination 2024–25 as specialised children’s hospitals), and excluding AR-DRGs from MDC 15 (newborns and other neonates).

The paediatric adjustment for each AR-DRG is:

1. Rounded to the nearest whole per cent.
2. Capped and floored at 200 per cent and 80 per cent respectively.
3. Set to one (that is, no adjustment) if the adjustment is less than 5 per cent either side of 100 per cent.

Further to this, the paediatric adjustment for the 2021–22 cost model is compared against that of the 2020–21 cost model and changes are stabilised for AR-DRGs where either of the cost data samples (that is, paediatric or non-paediatric) contain fewer than 500 observations. This stabilisation involves taking the average adjustment across the two years. The paediatric adjustments of the two years must also both be either above or below one, unless the previous year was one or missing.

The cost parameters of each AR-DRG are then calibrated to ensure that the modelled costs, with paediatric adjustment applied, are equal to the actual costs of the AR-DRG.

**Indigenous adjustment and patient residential remoteness adjustment**

These adjustments are derived by the following process:

1. The remoteness value for each episode is derived from an episode's available geographical information in the following order of preference: SA2, postcode, or the hospital geographical indicator variable.
2. A multivariate least squares weighted regression model is used to estimate the extent to which the variation in the mean cost per weighted episode is explained by each adjustment factor: Indigenous status, residential remoteness area, and radiotherapy and dialysis status.
3. Episodes are weighted to control the level to which the model already explains costs (that is, through the AR-DRG inlier/outlier model together with the paediatric adjustments). The coefficients estimated from this model indicate the extent to which each factor explains residual variation in costs.
4. The analysis yields an adjustment value for each of the adjustment categories.
5. The Indigenous adjustment taken as the cost-weighted mean of empirical adjustments taken from the admitted acute calculation above, and similar calculations applied to admitted subacute and non-acute, emergency care, and non-admitted code data.
6. The adjustments are additive where more than one adjustment applies, for example, where an Indigenous patient resides in a remote area, an adjustment equal to the addition of the Indigenous and remoteness adjustments is applicable.

**Radiotherapy and dialysis adjustment**

The dialysis adjustment is derived in the same way and at the same time as the Indigenous and remoteness adjustments, as described above.

Together with the radiotherapy adjustment, the adjustments compensate for the extra costs of dialysis-related and radiotherapy-related procedures, as specified in **Appendix B** and **Appendix C** of the National Efficient Price Determination 2024–25. These two adjustments are additive with the Indigenous and remoteness adjustments.

**Patient treatment remoteness adjustment**

The patient treatment remoteness adjustment was introduced in the NEP18 Determination. It is derived using the same methodology as the residential remoteness adjustment, and is designed to explain the residual variation in cost after the other adjustments have been applied. The analysis yields an adjustment for remote and very remote treatment locations.

**COVID-19 treatment adjustment**

The Coronavirus disease 2019 (COVID-19) treatment adjustment was introduced in the NEP24 Determination. It is derived using the same approach as the radiotherapy adjustment, and is designed to explain the residual variation in cost after the other adjustments have been applied for 2 AR-DRGs as specified in **Appendix P** of the National Efficient Price Determination 2024–‍25.

AR-DRG cost parameters are then uniformly calibrated to ensure cost neutrality of the model (including Indigenous, remoteness, radiotherapy, dialysis adjustments and COVID-19 treatment) against actual costs.

### 2.2.10 Private patient adjustments

Further adjustments are applied to private patients to account for the private benefit received from the Medicare Benefits Schedule (MBS) and private insurers. These adjustments cover the service and accommodation of private patients.

**Private patient service adjustment**

The HCP data provides a more accurate amount of benefits received from MBS and private insurers for medical hospital services and prostheses than provided by the NHCDC. These benefits are used to calculate the private patient service adjustment. The adjustment is calculated at the AR-DRG level for each jurisdiction, although for some AR-DRGs with small samples, the adjustment is derived at a more aggregate level. In the absence of data for a particular state or territory, a national value is used.

The following ratio was taken at the jurisdictional AR-DRG level:

Private patient service adjustment () = removed costs / total AR-DRG model costs

It should be noted that the AR-DRG model costs referred to in this document exclude the application of any other adjustments. That is, the private patient service adjustment () is calculated in such a way that it excludes any effect on the paediatric, Indigenous, remoteness, and radiotherapy or dialysis adjustments.

The AR-DRG cost parameters are then uniformly calibrated to ensure cost neutrality of the cost model (including the private patient service adjustment and previously derived adjustments) against actual costs.

**Private patient accommodation adjustment**

In addition to medical and prostheses costs, insurers are also charged for accommodation. A private patient accommodation adjustment () is applied to account for revenue received in relation to these charges. For the purpose of deriving the adjustment associated with NEP24, 2023–24 average default benefits for private health insurers by state/territory are indexed forward one year by 3.75 per cent (that is, by the Consumer Price Index as required by legislation) to 2024–25.

### 2.2.11 Funding adjustment for HACs

The Addendum to the NHRA, signed in March 2017, required IHACPA to develop an approach for funding episodes which have a HAC for implementation by 1 July 2018. IHACPA developed an additional adjustment to account for a HAC episode included in the calculation of NWAU and is included in the NWAU calculation formula, see Section 2.3.

A detailed explanation of the funding adjustment can be found in the accompanying document ‘National Pricing Model Risk adjustments for hospital acquired complications – Technical Specifications 2024–25’ on the IHACPA website.

Funding adjustments for HACs are not applicable for COVID-19 patients flagged as per **Appendix B** in the variable row labelled A0.

### 2.2.12 Funding adjustment for AHR

The Addendum to the NHRA, signed in May 2020, required IHACPA to develop an approach for funding episodes which have an AHR, ready for implementation from 1 July 2021. IHACPA has developed an adjustment for episodes that result in an AHR.

A detailed explanation of the funding adjustment can be found in the accompanying document ‘National Pricing Model Risk adjustments for avoidable hospital readmissions – Technical Specifications 2024–25’ on the IHACPA website.

Funding adjustments for AHRs are not applicable for COVID-19 patients flagged as per **Appendix B** in the variable row labelled A0.

### 2.2.13 Incorporation of outlier samples of cost data

The development of the cost model to this point is based on the sample of patient-level cost data evaluated as fit for use to develop AR-DRG cost profiles. Thus, the sample of patient-level cost data identified as not fit for use at the AR-DRG level have not been used within the cost model.

The following process is used to calibrate the cost model against the entire sample of cost data:

1. The cost model developed to this point, including all adjustments (except the private patient adjustments) is applied to the entire cost data sample. This process results in model costs across the entire sample of cost data.
2. The AR-DRG cost parameters are then uniformly adjusted to ensure the resulting total modelled cost across the entire sample is equalised against the total actual costs of the entire sample.

It should be noted again that sample-to-population weights are used throughout all stages in the development of the cost model.

### 2.2.14 Account for COVID-19 in the admitted acute cost model

The 2021–22 data used to set the NEP24 includes activity and cost data collected during significant waves of the COVID-19 pandemic. Following extensive analysis of admitted acute data, activity was shown to vary significantly from post-COVID-19 activity growth trends in the 2021–22 year. Consequently, admitted acute price weights for NEP24 include an adjustment to prospectively account for the impact of COVID-19.

The 2021–22 admitted acute cost model was adjusted in order to calculate the reference cost in three stages:

1. Model the variation in national admitted acute activity levels during 2021–22, relative to the post-COVID-19 trend.
2. Normalise activity throughout 2021-22 by inflating activity to be on trend with post-COVID-19 activity growth experience.
3. Inflate costs to incorporate additional flexible costs for normalised activity not funded by the National Partnership on COVID-19 Response minimum funding guarantee (MFG).

For part (a), monthly activity levels from July 2015 to March 2023 were analysed to understand the impacts of COVID-19 and lockdowns on activity levels over time. This model showed a 3.40 per cent decrease in activity in 2021–22, after accounting for potential enduring effects of COVID-19 and lockdown events. Equivalently, 2021–22 activity was at 0.9660 times the expected activity level for the period.

For part (b), the activity throughout 2021–22 is inflated by a factor of 1.0352 (1/0.9660), effectively adding an additional 206,140 GWAU to the model. Based on the cost of activity through 2021–22, it is assumed that 110,271 of the added GWAU are already accounted for in the NHCDC due to the MFG. This leaves a further 95,869 GWAU for which costs should be adjusted.

In part (c), actual costs are inflated by $96.6 million to account for flexible costs for the GWAU not covered by the MFG. The flexible cost component is based on the non-labour costs, such as the direct cost component of pathology, imaging, prostheses, medical and surgical supplies, other goods and services, non-PBS pharmacy and hotel line items in the NHCDC.

In total, the empirical 2021–22 cost parameters are recalibrated by a factor of 0.966511 to account for both decreased activity reporting and an estimated increase in input costs that are expected to be ongoing in 2024–25.

### 2.2.15 Price weights and NWAU

The final step in the process involves the conversion of the 2021–22 cost model parameters to cost weight values by dividing the cost parameters by a reference cost.

The reference cost used was the 2020–21 reference cost indexed one year by the growth rate in the consecutive years’ cost models, where this growth rate is standardised against the 2021–22 activity data. Specifically, the standardised growth rate was derived by applying the 2019–20 and 2021–22 cost models (excluding private patient adjustments) to the 2021–22 activity data, and calculating the change in total modelled costs between the two models.

For NEP24, the standardised growth rate calculation follows the same methodology used to calculate the 2020–21 reference cost from the 2019–20 reference cost.

The resulting cost weights are then converted to the price weights that are used to assign NWAU, as explained further in Section 7.

### 2.2.16 Stabilisation of acute weights

The National pricing model stability policy (the Stability policy) states that inlier price weight movements between years will be capped to ±20 per cent for AR-DRGs deemed comparable between years where the impact will be minimal.

Stabilisation of inlier weights is done simultaneously. An adjustment factor is calculated for each cost parameter so that the associated price weight is ±20 per cent of the previous year’s price weight.

This adjustment factor is then applied to the same-day, short-stay base, and short-stay outlier per diem weights if they exist. Long-stay outlier per-diem weights are not scaled in this way in order to avoid potential unintended extreme cost ratios for very long-stay outliers. The entire cost model is then recalibrated to ensure that the total actual costs and the total modelled costs are equal across the entire sample.

For NEP24, two admitted acute end-classes, A40Z *ECMO* and V64A *Other drug use and dependence, major complexity* were not stabilised following advice that costs were likely driven by COVID-19 related changes to the model and cost of care.

## 2.3 Applying the NEP

The price of an ABF activity is calculated using the following formula, with adjustments applied as applicable:

**Price of an admitted acute ABF activity**

Where:

**APaed**means the paediatric adjustment

**ARes**means each or any patient residential remoteness area adjustment

**AInd**means the Indigenous adjustment

**ART**means the radiotherapy adjustment

**ADia** means the dialysis adjustment

**ATreat** means each or any patient treatment remoteness area adjustment

**AC19** means the COVID-19 treatment adjustment

**AICU** means the intensive care unit (ICU) adjustment

**APPS**means the private patient service adjustment

**AAcc** means the private patient accommodation adjustmentapplicable to the state of hospitalisation and length of stay

**AHAC** means the hospital acquired complications adjustment factor

**AAHR** means the avoidable hospital readmission risk adjustment factor

**ICU hours** means the number of hours spent by a person within a specified ICU

**LOS** means length of stay in hospital (in days)

**NEP** means National Efficient Price 2024–25

**PW** means the price weight for an ABF activity as set out at **Appendix H** of the National Efficient Price Determination 2024–25

**PWAHR** price weight for an ABF activity of a linked avoidable hospital readmission.

In the event that the application of the private patient adjustments return a negative NWAU(24) value for a particular patient, the NWAU(24) value is held to be zero; that is, negative NWAU(24) values are not permitted for any patients under the national pricing model.

Table 2 and Table 3 outline the information required to apply the above formula.

Table 2: Dataset and tables required for assignment of NWAU to admitted acute patient data

| **Input dataset or table** | **Description** |
| --- | --- |
| APC NMDS | Dataset based on the 2021–22 Admitted Patient Care National Minimum Data Set (APC NMDS). |
| ICU Rate and Paediatric Adjustment eligibility table | Table listing establishments with an eligible ICU or PICU, found in the National Efficient Price Determination 2024–25 and Glossary. |
| Postcode table | Table of postcodes mapped to the 2021 ASGS Remoteness Area classification. Each postcode is mapped to the Remoteness Area category within which the majority of the postcode’s population resides. PO Box postcodes are mapped to the Remoteness Area category within which the Post Office is located. |
| ASGS table | Table of Australian Statistical Geography Standard (ASGS) mapped to the Remoteness Area category within which the majority of the ASGS’s population resides. |
| 2024–25 NWAU Price weight table | 2024–25 Admitted acute NWAU Price weight table, found in the National Efficient Price Determination 2024–25. |
| 2024–25 NWAU Adjustments | 2024–25 Admitted acute NWAU Adjustments, found in the National Efficient Price Determination 2024–25. |

Table 3: APC NMDS variables used to calculate 2024–25 admitted acute NWAU.

| **APC NMDS Variable** |
| --- |
| State identifier |
| Establishment identifier |
| Hospital geographical indicator |
| Sex |
| Date of birth |
| Date of admission |
| Date of separation |
| Care type |
| Admission mode |
| Admission urgency status |
| Number of qualified days for newborns |
| Total psychiatric care days |
| Indigenous status |
| Funding source[[7]](#footnote-8) |
| Australian refined diagnosis related group v11.0 |
| Total leave days |
| Total Hours spent in intensive care unit |
| Postcode of patient's usual residence |
| Australian Statistical Geography Standard (ASGS) of patient's usual residence |
| Either the identifier signifying radiotherapy treatment or the list of patient’s ICD-10-AM procedure codes. |
| Either the identifier signifying dialysis or the list of patient’s ICD-10-AM procedure codes. |
| Either the identifier signifying COVID-19 treatment or the list of patient’s ICD-10-AM procedure codes. |
| The list of patient’s ICD-10-AM codes, including diagnoses and condition onset flags. |

# 3. Mental health care cost model

## 3.1 General issues

### 3.1.1 Cost unit

A ‘mental health phase of care’[[8]](#footnote-9) is the cost unit for mental health patients. A phase of care is ‘a distinct clinical period which reflects the goal of treatment of mental illness.’ It ‘begins either when a patient commences an episode of mental health care (MHC) or when the primary goal of care changes in an existing MHC episode’[[9]](#footnote-10) and ‘ends either when a patient concludes an episode of MHC or when the primary goal of care changes in an existing mental health care episode.’[[10]](#footnote-11)

### 3.1.2 In-scope activity

Admitted mental health care is that provided to patients who undergo a facility’s formal admission[[11]](#footnote-12) processes.

MHC activity is submitted under the ABF MHC NBEDS, which considers MHC activity across admitted, emergency, ambulatory and residential settings as in-scope. Therefore, in-scope admitted MHC activity is identified by a service setting variable supplied by jurisdictions, according to IHACPA’s data request specifications.[[12]](#footnote-13) If service setting is missing, a phase is determined to be admitted care if it is able to be linked to an admitted patient care episode and/or it has a non-missing admitted service unit identifier.

Mental health patients receiving emergency department and non-admitted care services are not differentiated in NEP24 and so receive payments as defined for the relevant ABF product category.

### 3.1.3 Classification

The Australian Mental Health Care Classification (AMHCC) is used to classify admitted mental health care patients. The version that applies for funding in 2024–‍25­ is AMHCC Version 1.0.

## 3.2 Analysis of costs to derive NWAU for mental health care

### 3.2.1 Data sources

The activity data collection that informs the NEP24 admitted mental health cost model is the Activity Based Funding: Mental Health Care National Best Endeavours Data Set (ABF MHC NBEDS) for 2021–22. For mental health care, data is reported by states and territories at two levels:

* Episode of mental health care – supplied to IHACPA in the ABF Mental Health Care Episode (MHCE) file.
* Mental health phase of care – supplied to IHACPA in the ABF Mental Health Care Phase (MHCP) file.

This is used in combination with care type[[13]](#footnote-14) 11 - Mental health caredata from the 2021–22 APC NMDS, which also provides episode-level data including funding source and mental health legal status.

Cost data is reported through 2021–22 collection of the NHCDC, which may be reported by states and territories at either the phase level (preferred) or the episode level. Linkage between activity and cost data sets is illustrated in Figure 4.

**Figure 4: Mental health activity and cost data linkage**

Diagram

Description automatically generated with low confidence

### 3.2.2 Data preparation

After data linkage, a range of steps were undertaken to prepare the data for input to the cost model:

* Where the same variables are present across both files, variables are condensed to a single field, generally giving preference to the APC data (as this is a more mature data set). For example, a non-missing value for Indigenous status from the APC data is used in preference to the value from the MHCE data set.
* Phase dates are cleaned such that:
  + If phase start date is missing but phase end date is not missing, and if the episode admission date is less than or equal to the phase end date, then the phase start date is set equal to the episode admission date.
  + If phase end date is missing but phase start date is not missing, and if the episode separation date is greater than or equal to the phase start date, then the phase end date is set equal to the episode separation date.
  + If both phase start and end dates are missing then the episode admission and discharge dates are adopted. This means that episodes that are not linked to phase data are considered phases with unknown phase type.
  + Age is recalculated based on the cleaned phase dates, thereby preferencing patient age at the start of the phase and otherwise using the age at episode start.
  + The AMHCC v1.0 grouper is then re-applied to the data, in order to get the most accurate grouping based on the linked data, followed by linkage of remoteness variables as per the admitted acute model.
  + Blood and PBS costs are removed from patient costs.

To refine the data to be used for modelling, steps are then taken to trim the data, as outlined in Table 4.

**Table 4: Number of episodes trimmed at each data preparation stage**

|  |  |  |
| --- | --- | --- |
| **Trimming stage** | | **Admitted Records** |
| (a) Initial activity-level sample of mental health records | | **148,368** |
| (b) Initial activity-level cost sample of mental health records | | **116,187** |
| **Less** – Total trimmed episodes | | **-15,033** |
|  | (c) Phases records with non-unique or non-phase-level costs | **-12,011** |
| (f) Work in progress[[14]](#footnote-15) | **-103** |
| (g) Error phase dates/phase length | **-2,052** |
| (i) Patient level cost data trimmed under jurisdictional advice | **-139** |
| (j) Phases from hospital-AMHCC combinations with extremely high or low cost-to-price ratios | **-154** |
| (k) Removal of records with total in-scope costs < $15 | **-3** |
| (l) Observations with extreme outlier costs | **-4** |
| (m) Extremely high or low cost ratios removed after deriving the preliminary regression model | **-567** |
| (n) Resulting sample size of phases used to create AMHCC cost profiles | | **101,154** |

### 3.2.3 Private patient costs

As in the admitted acute care cost model (Section 2.2.3), HCP data is used to correct for the missing private patient costs in the NHCDC for admitted mental health records, as well as for subsequent estimates of private patient service adjustments.

A total of 63 per cent of phases with a private insurance funding source were able to be matched to benefits in the HCP dataset, with the remaining unmatched records assumed to have similar characteristics to the matched dataset. A correction factor was then calculated at the jurisdiction level to estimate and account for the amount of private patient costs not included in NHCDC.



### 3.2.4 Inlier bounds

Inlier bounds for admitted AMHCC classes are calculated similarly to the way they are calculated for AR-DRGs in the admitted acute cost model.

With the exception of combined classes 131 and 141 (where the A, B and Z complexity categories are modelled under a per diem), the inlier bounds for admitted AMHCC classes were set using the L1.5H1.5[[15]](#footnote-16) trimming method, as shown in Figure 5. This is in line with the previous trimming method applied to major diagnostic categories 19 and 20 when admitted mental health was costed under the AR-DRG cost model, because the narrower bounds generated a lower proportion of inliers and higher proportion of short-stay and long-stay outliers. For combined AMHCC classes with fewer than 50 observations, a per diem model is adopted instead of the inlier/outlier model. Hence, the inlier bounds are not applicable for these classes. This applies to combined classes 131 and 141.

Inlier lower bounds are truncated while inlier upper bounds are rounded to the nearest integer, as per the admitted acute model (Section 2.2.5). Phases with a length of stay equal to or between the two inlier bounds of the AMHCC are considered inlier phases.

**Figure 5: Inlier bound calculations for mental health using the L1.5H1.5 trimming method**



Mental health inlier phase

Inlier bounds are subject to the same stabilisation methodology as that which is applied to AR‑DRG classes in the admitted acute cost model. If the 95 per cent confidence interval around each NEP24 AMHCC inlier bound does not contain the corresponding NEP23 AMHCC inlier bound, movements are evaluated for materiality. If movements impact the separation category of at least 1 per cent of separations and at least 10 separations in the AMHCC class, the inlier bound is stabilised to the corresponding NEP23 inlier bound. If the average length of stay of a particular end-class falls outside the previous NEP23 inlier lower and upper bounds, then the changes in bounds will be implemented even if they do not meet the stability and materiality considerations above.

Additionally, there is a check on whether the previous inlier bounds for the end-class were subject to the same grouping or capping to ensure modelling comparability between years. Where the end-class is directly comparable to the previous NEP23, the inlier bounds are used for stabilisation. Comparable end-classes are determined as follows:

* Not capped and not grouped in NEP23 and NEP24;
* Same grouping NEP23 and NEP24;
* *B* capped in NEP23 and not grouped in NEP24 or vice versa; or
* *Z* is not capped or grouped in NEP23 and capped in NEP24.

### 3.2.5 Stratification and weighting

The sample of admitted AMHCC classified data is weighted to account for the fact that it excludes all activity with an admission date prior to 1 July 2020.

### 3.2.6 Cost parameters

The cost parameters of the admitted AMHCC inlier/outlier model are calculated in the same way as those for AR-DRGs, with the exception of:

* The use of inlier bounds defined by L1.5H1.5 instead of L3H3.
* Modelling the short-stay outlier base as the intercept of a per diem model instead of modelling ‘same day’ fixed costs explicitly. It is assumed the short-stay outlier base is the cost of a phase when the patient is admitted and discharged on the same date.
* Modelling costs for grouped AMHCC classes where data is sparse and/or the relationship between Moderate and High HoNOS complexity is counterintuitive, such as when a Moderate complexity class has higher modelled costs than High complexity for 50 per cent or more of High HoNOS inliers. For the 2021–22 model, this applies to 121, 123, 133, 142 and 143.
* The use of a per diem model for combined AMHCC classes 131 and 141, where same-day phases receive a short-stay outlier base price, plus a long-stay outlier per diem for overnight admissions.
* Capping Unknown HoNOS class inlier cost parameters such that they do not exceed the inlier cost for the corresponding Moderate HoNOS class. For the 2021–22 model, this applies to 111Z, 1121Z, 1122Z and 122Z. This ensures there is no disincentive to reporting HoNOS data.

### 3.2.7 Adjustments

A single paediatric adjustment is derived using a univariate least squares weighted regression model. This is used to estimate the extent to which the variation in the mean cost per weighted phase is explained by specialised paediatric status.

Specialised paediatric patients are identified as being less than or equal to 17 years of age and admitted at an establishment identified as delivering specialised paediatric services (listed in **Appendix E** of the National Efficient Price Determination 2024–25).

Episodes are weighted to control the level to which the inlier/outlier model already explains costs. The coefficient estimated from this model indicates the extent to which specialised paediatric status explains residual variation in costs and is used to calculate an adjustment value to account for this.

A number of other adjustments, calculated by the admitted acute model, are also applied to admitted mental health patients. The relevant adjustments applied are the:

* Patient residential remoteness area adjustment
* Indigenous adjustment
* Patient treatment remoteness area adjustment

The private patient service adjustment is calculated by AMHCC class and jurisdiction using the same methodology used in the admitted acute cost model. The derivation of the private patient accommodation adjustment is outlined in Section 2.2.10.

The proportion of cost model data for which the adjustments apply are as follows:

* Paediatric adjustment: 4.0 per cent
* Patient residential remoteness area adjustment: 9.4 per cent
* Indigenous adjustment: 10.3 per cent
* Patient treatment remoteness area adjustment: 0.8 per cent
* Private patient adjustments: 6.9 per cent.

Following the application of these adjustments (excluding the private patient adjustments), the cost parameters are uniformly adjusted to ensure the resulting total modelled cost is equalised against the total actual costs.

### 3.2.8 Admitted mental health care stabilisation

IHACPA’s Stability Policy has been applied to limit the change in price weights of each AMHCC class between NEP23 and NEP24. This policy applies to every AMHCC class with the same inlier bounds in NEP23 and NEP24 and for which fewer than inlier 1,000 separations were used in the admitted mental health care cost model. Where these conditions are met, price weights are adjusted to be within 20 per cent of the price weight for that class in NEP23.

Refer to Section 2.2.16 for information about the stabilisation process.

### 3.2.9 Price weights and NWAU

Price weights are obtained by dividing the dollar-valued cost parameters by the reference cost (derived in the admitted acute cost model). These price weights are used to assign NWAU, as explained further in Section 7.

### 3.2.10 Apply the NEP

The price of an ABF activity is calculated using the following formula, with adjustments applied as applicable:

**Price of an admitted mental health ABF activity**

Where:

**APaed**means the paediatric adjustment

**ARes**means each or any patient residential remoteness area adjustment

**AInd**means the Indigenous adjustment

**ATreat** means each or any patient treatment remoteness area adjustment

**APPS**means the private patient service adjustment

**AAcc** means the private patient accommodation adjustmentapplicable to the state of hospitalisation and length of stay

**LOS** means the length of stay in hospital (in days) for the phase of care

**NEP** means National Efficient Price 2024–25

**PW** meanstheprice weight for an ABF activity as set out at **Appendix J** of the National Efficient Price Determination 2024–25

In the event that the application of the private patient adjustments return a negative NWAU(24) value for a particular patient then an NWAU(24) of zero is assigned to that patient.

Table 5 and Table 6 outline the information required to apply the above formula.

**Table 5: Datasets and tables used for assignment of NWAU to admitted mental health patient data**

| **Input dataset or table** | **Description** |
| --- | --- |
| MHC NBEDS | Dataset based on the 2021–22 Activity based funding: Mental health care National Best Endeavours Data Set (MHC NBEDS). |
| APC NMDS | Dataset based on the 2021–22 Admitted Patient Care National Minimum Data Set (APC NMDS). |
| Paediatric Adjustment eligibility table | Table listing eligible specialised children’s hospitals, found in the National Efficient Price Determination 2024–25 and Glossary. |
| Postcode table | Table of postcodes mapped to the 2021 ASGS Remoteness Area classification. Each postcode is mapped to the Remoteness Area category within which the majority of the postcode’s population resides. PO Box postcodes are mapped to the Remoteness Area category within which the Post Office is located. |
| ASGS table | Table of Australian Statistical Geography Standard (ASGS) mapped to the Remoteness Area category within which the majority of the ASGS’s population resides. |
| 2024–25 NWAU price weight table | 2024–25 Admitted mental health NWAU Price weight table, found in the National Efficient Price Determination 2024–25. |
| 2024–25 Admitted Acute NWAU Adjustments | 2024–25 Admitted acute NWAU Adjustments, found in the National Efficient Price Determination 2024–25. |

**Table 6: Phase level variables (based on MHC NBEDS and APC NMDS variables) used to calculate 2024**–**25 admitted mental health NWAU**

| **MHC NBEDS and APC NMDS variables** |
| --- |
| State identifier |
| Establishment identifier |
| Hospital geographical indicator |
| Date of birth |
| Phase start date |
| Phase end date |
| Indigenous status |
| Mental health legal status |
| Funding source[[16]](#footnote-17) |
| AMHCC class |
| Total leave days |
| Postcode of patient's usual residence |
| Australian Statistical Geography Standard (ASGS) of patient's usual residence |

# 4. Admitted subacute and non‑acute care cost model

## 4.1 General issues

### 4.1.1 General issues cost unit

An ‘episode of admitted patient care’[[17]](#footnote-18) is the cost unit for admitted subacute and non-acute patients. It is ‘the period of admitted patient care… characterised by only one care type’ [[18]](#footnote-19), and covers the period of care from admission to separation.

### 4.1.2 In-scope activity

Admitted subacute and non-acute care is that provided to patients who undergo a facility’s formal admission[[19]](#footnote-20) process, where the clinical intent or treatment goal is the provision of subacute or non-acute care.

In-scope hospitals and patients are defined the same way as admitted acute patients, except that the patients are admitted into a care type for subacute or non-acute care.

### 4.1.3 Classification

Version 5.0 of the Australian National Subacute and Non-Acute Patient Classification (AN‑SNAP) is used to classify admitted subacute and non-acute care. Where data required to assign an AN‑SNAP classification is not available, the episodes are moved into the admitted acute care cost model. Episodes without a valid AN-SNAP end class are transferred to the admitted acute care model and priced according to their AR-DRG classification.

## 4.2 Analysis of costs to derive NWAU for subacute and non-acute admitted care

The following steps are taken in developing the cost parameters and weights for admitted subacute and non-acute care:

1. Data preparation.
2. Develop sample-to-population weights.
3. Classify AN-SNAP episodes into relevant categories: inliers, short-stay and   
   long-stay outliers using the ABF L1.5H1.5 methodology.
4. Apply Indigenous, radiotherapy, dialysis, and remoteness adjustments inherited from the admitted acute care cost model.
5. Derive private patient service adjustments for each care type and jurisdiction.

These steps are described in more detail in the following sections.

### 4.2.1 Data preparation

The 2021–22 admitted subacute and non-acute cost sample consists of the following groups in Table 7.

Table 7: Admitted subacute cost sample breakdown

| **Group** | **Establishments** | **Total records** | **Total days** |
| --- | --- | --- | --- |
| Total National Hospital Cost Data Collection (NHCDC) sample | 251 | 210,904 | 2,732,935 |
| AN-SNAP classified data | 263 | 208,226 | 2,736,349 |

The costs of care associated with other Commonwealth programs for blood costs and pharmaceuticals are removed from NHCDC costs in the same manner described for the admitted acute model in Section 2.2. When costs are reported at the episode level but must be deducted from the reported cost of multiple phases of a palliative care episode, deductions are attributed to each phase according to the proportion of pre-deduction in-scope costs accrued at that phase.

As in the admitted acute care cost model, HCP data is used to correct for the missing private patient costs in the NHCDC, as well as for subsequent estimates of private patient service adjustments (see Section 2.2.10).

The data is trimmed for extreme outliers using similar methodology to the admitted acute care cost model. The following data was not used to derive the AN-SNAP Version 5.0 cost profiles:

* Records that had an in-scope cost of $0.
* Records with an error AN-SNAP Version 5.0 class.
* Records pertaining to persons under the age of 18 with an AN-SNAP Version 5.0 class within either Psychogeriatric Care or Geriatric Evaluation and Management care types.
* Records pertaining to persons under the age of 18 with an AN-SNAP Version 5.0 class that does not correspond to a paediatric AN-SNAP Version 5.0 class.
* Records that had not been assigned an AN-SNAP Version 5.0 class.
* Extreme cost outliers within an AN-SNAP Version 5.0 class.

### 4.2.2 Stratification and weighting

The sample of AN-SNAP classified data is weighted to account for the fact that the used sample excludes all activity with an admission date prior to 1 July 2020.

### 4.2.3 Inlier Bounds

Inlier bounds for each AN-SNAP Version 5.0 class, other than same-day classes, are determined using the L1.5H1.5 methodology described in Section 2.2.5. The inlier bounds of each AN-SNAP Version 5.0 class are subject to the same stabilisation methodology as that which is applied to AR-DRG classes in the admitted acute model. This process limits the degree to which inlier bounds are liable to change as a result of statistical noise. This policy dictates that if the inlier lower bound in NEP23 is within a 95 per cent confidence interval (with respect to a normal distribution) of the lower bound calculated for NEP24 then the lower bound in NEP23 is also used in NEP24. The same rule is applied to the inlier upper bound.

Moreover, even if the previous year’s bounds are outside these confidence intervals, changes in bounds are only implemented if doing so is considered material. Changes are considered material if they impact the separation category of at least 1 per cent of separations in a given AN‑SNAP class and at least 10 separations in that class.

IHACPA’s Stability Policy has been applied to limit the change in price weights of each AN-SNAP class between NEP23 and NEP24. This policy applies to every AN-SNAP class with the same inlier bounds in NEP23 and NEP24 and for which fewer than 1,000 separations were used in the admitted subacute model. In line with the Stability Policy, the price weight of such a class must be within 20 per cent of the price weight of the same class in NEP23.

If the average length of stay of an AN-SNAP class falls outside the inlier lower and upper bounds, then the changes in bounds will be implemented even if they do not meet the stability and materiality considerations above.

### 4.2.4 Determining AN-SNAP Version 5.0 cost parameters

The AN-SNAP cost model parameters comprise the following:

* Same-day price weight: applicable to records within a same-day AN-SNAP class.
* Short-stay outlier per diem rate: applicable to records which do not belong to a same-day AN-SNAP Version 5.0 class and have a length of stay shorter than the inlier lower bound.
* Inlier episodic rate: applicable to records which do not belong to a same-day AN-SNAP Version 5.0 class and which have a length of stay greater than or equal to the inlier lower bound for their AN-SNAP Version 5.0 class.
* Long-stay outlier per diem rate: applicable to records which do not belong to a same-day AN‑SNAP Version 5.0 class and which have a length of stay longer than the inlier upper bound for their AN-SNAP Version 5.0 class.

### 4.2.5 Calculation of additional adjustments

The following adjustments are applied within the admitted subacute cost model:

* Private patient service adjustment: This adjustment is calculated by care type and jurisdiction in the same manner as that which is calculated for AR-DRGs within the admitted acute cost model.
* A number of other adjustments are derived within the admitted acute cost model and applied in the subacute stream:

1. Indigenous
2. residential remoteness
3. radiotherapy
4. dialysis
5. treatment remoteness.

The proportion of NHCDC activity for which the adjustments apply are as follows:

* The Indigenous adjustment applied to 2.5 per cent of subacute activity.
* The residential remoteness adjustment applied to 8.0 per cent of subacute activity.
* The radiotherapy adjustment applied to 0.6 per cent of subacute activity.
* The dialysis adjustment applied to 0.7 per cent of subacute activity.
* The treatment remoteness adjustment applied to 0.4 per cent of subacute activity.
* The private patient adjustments applied to 17.0 per cent of subacute activity.

The cost model (including all adjustments except the private patient adjustments) is then calibrated to ensure that the sum of model costs in the subacute cohort is the same as that of in‑scope costs.

### 4.2.6 Subacute and non-acute stabilisation

Refer to Section 2.2.16 for information about the stabilisation process. The same methodology has been applied to the admitted subacute and non-acute cost model.

For NEP24, one sub-acute end-class, 5O01 *Paediatric same-day rehabilitation* was not stabilised following advice that costs were likely driven by COVID-19 related changes to the model and cost of care.

### 4.2.7 Price weights and NWAU

Price weights are obtained by dividing the dollar-valued cost parameters by the reference cost (from the admitted acute care cost model). The same reference cost is used across all streams of activity and is discussed in Chapter 7.

### 4.2.8 Applying the NEP

As set out in the National Efficient Price Determination 2024–25, the price of an ABF admitted subacute activity is calculated using the following formula, with adjustments applied as applicable:

**Price of an admitted subacute ABF activity**

Where:

**AInd**means the Indigenous adjustment

**ARes**means each or any patient residential remoteness area adjustment

**ART**means the radiotherapy adjustment

**ADia** means the dialysis adjustment

**ATreat** means each or any patient treatment remoteness area adjustment

**APPS**means the private patient service adjustment, determined by care type and state of hospitalisation.

**AAcc** means the private patient accommodation adjustmentdetermined by the state of hospitalisation and length of stay

**LOS** means length of stay in hospital (in days)

**NEP** means National Efficient Price 2024–25

**PW** means the price weight for an ABF activity as set out in **Appendix I** of the National Efficient Price Determination 2024–25

In the event that the application of the private patient accommodation adjustment and the private patient service adjustment returns a negative NWAU value for a patient then an NWAU of zero is assigned to that patient.

Table 8 outlines the required information in order to apply the above formula.

Table 8: Datasets and tables used for assignment of NWAU to admitted subacute patient data

| **Input dataset or table** | **Description** |
| --- | --- |
| APC NMDS and ASNHC DSS | Dataset based on the Admitted Patient Care National Minimum Data Set (APC NMDS), with extra AN‑SNAP information from the Admitted Subacute and Non-acute hospital care DSS (ASNHC DSS), where available. Dataset specifications are located on the IHACPA website. |
| Postcode table | Table of postcodes mapped to the 2021 Australian Statistical Geography Standard (ASGS) remoteness area classification. Each postcode is mapped to the remoteness area category within which the majority of the postcode’s population reside. PO Box postcodes are mapped to the remoteness area category within which the Post Office is located. |
| ASGS table | Table of ASGS codes mapped to the remoteness area category within which the majority of the population of the ASGS resides. |
| 2024–25 NWAU price weight tables | 2024–25 NWAU admitted subacute and non-acute AN-SNAP and care type same-day and overnight per diem price weight tables, found in the National Efficient Price Determination 2024–25. |
| 2024–25 NWAU adjustments | 2024–25 NWAU admitted subacute and non-acute adjustments, found in the National Efficient Price Determination 2024–25. |

Sixteen variables are required to form the input APC dataset. These variables form part of the APC NMDS and the ASNHC DSS are on the IHACPA website and are listed in Table 9.

Table 9: APC and ASNHC DSS variables used to calculate 2024–25 admitted subacute NWAU

| **Dataset** | **Variable** |
| --- | --- |
| APC NMDS | State identifier |
| Hospital geographical indicator |
| Date of birth |
| Date of admission |
| Date of separation |
| Care type |
| Indigenous status |
| Funding source |
| Total leave days |
| Postcode of patient's usual residence |
| Australian Statistical Geography Standard (ASGS) of patient’s usual residence |
| Either the identifier signifying radiotherapy treatment or the list of patient’s ICD-10-AM procedure codes. |
| Either the identifier signifying dialysis or the list of patient’s ICD-10-AM procedure codes. |
| ASNHC DSS | AN-SNAP class (Version 5.0) |
| Palliative phase of care start date |
| Palliative phase of care end date |

# 5. Emergency care cost model

## 5.1 General issues

### 5.1.1 Cost unit

The cost unit for ABF for emergency care is an ‘emergency department stay’[[20]](#footnote-21) or presentation. It includes stays for patients who are treated and go home, and ones who are subsequently admitted to hospital or transferred to another facility for further care.

### 5.1.2 Scope

Emergency care is that provided to patients registered for care in an emergency department within a selected public hospital. Patients declared dead on arrival are considered in-scope if the death is certified by an emergency care clinician. Patients who leave emergency care after being triaged and advised of alternative treatment options, are also considered in-scope. All patients in the ABF emergency services care (ESC) data set specification (ABF ESC DSS) are in-scope.

Patients being treated in emergency departments may subsequently undergo a formal admission process. All patients remain in-scope for ABF for emergency care until they are recorded as having physically departed the emergency department, regardless of whether they have been admitted.

### 5.1.3 Classification

Two systems are used to classify emergency care for the purposes of ABF: Australian Emergency Care Classification (AECC) Version 1.0 and Urgency Disposition Groups (UDGs) Version 1.3. The former applies to level 3B to level 6 emergency departments, and the latter to emergency services (that is, levels 1 to 3A). The levels are defined in the National Efficient Price Determination 2024–25 – Online Glossary.

## 5.2 Analysis of costs to derive NWAU for emergency care

### 5.2.1 Data preparation

NHCDC Round 26 reported 8,029,171 presentations in 199 ABF establishments with patient-level cost data. This represents 96 per cent of the total emergency care population as reported in the ABF DSS datasets and NHCDC.

IHACPA undertook an initial data preparation process in line with that employed for NEP23, including the removal of out-of-scope blood, pharmaceutical, and teaching costs. The cleansed data is episode level data grouped by AECC or UDG. The following data was not used in deriving relativities across AECCs and UDGs, but was used to calibrate the overall cost level of the model:

* Presentations that grouped to error AECCs due to missing or invalid data fields.
* Presentations that were less than $5.
* Extreme cost outliers within each AECC class.
* Presentations at establishments with an extreme cost ratio.

### 5.2.2 Sample weights

The NHCDC provides a sample of emergency care activity in public hospitals. To ensure the resulting calculations for the NWAU are appropriate for the full population of emergency care activity, observations from the NHCDC are weighted up to reflect the entire population of emergency care activity by state or territory.

### 5.2.3 Cost parameters and adjustments

Data enters the cost model in three levels, by presentation at the AECC level and UDG level, and at an aggregate UDG level. It is possible for an episode to have an AECC and a UDG associated to it. The AECC data is combined, and price weights are calculated. The same process is used for UDGs. Price weights are calibrated to ensure that AECC and UDG cost models return total actual costs at a national level.

The approach to pricing emergency care services incorporates an adjustment for Indigenous status, patient remoteness, and treatment remoteness. The Indigenous adjustment is a weighted average calculated across the admitted acute, admitted subacute and non-acute care, emergency department and non-admitted streams. The patient residential area remoteness adjustment is a single adjustment derived and applied to patients assigned to remote and very remote locations, and the patient treatment remoteness area adjustment is calculated and applied in a similar manner. The Stability Policy requires that the year-to-year movements in price weights are capped at 20 per cent.

For NEP24, one emergency department end-class, E1820C *Viral illnesses, Complexity level C* was not stabilised following advice that costs were likely driven by COVID-19 related changes to the model and cost of care.

### 5.2.4 Price weights and NWAU

The final step of the process involves the conversion of cost parameters to cost weights. This is done by dividing the AECC and UDG cost parameters by the reference cost for the admitted acute cost model. These cost weights are then converted to the price weights used to calculate the NWAU.

The price of an emergency care ABF activity is calculated using the following formula with adjustments as applicable.

**Price of an emergency care or emergency service ABF activity**

Where:

**AInd**means the Indigenous adjustment (emergency departments only)

**ARes**means each or any patient residential remoteness area adjustment (emergency departments only)

**ATreat**means each or any patient treatment remoteness area adjustment

**NEP** means National Efficient Price 2024–25

**PW** means the price weight for an ABF activity as set out in **Appendix L** (for emergency department) or **Appendix M** (for emergency services) of the National Efficient Price Determination 2024–25.

Table 10 outlines the required information in order to apply the above formula.

Table 10: Dataset and tables required for assignment of NWAU to emergency department patient data

| **Input dataset or table** | **Description** |
| --- | --- |
| NAPEDC NMDS | Non-admitted patient emergency department care national minimum data set (NAP EDC NMDS). |
| 2024–25 NWAU price weight tables | 2024–25 emergency care NWAU AECC and UDG price weight tables, found in the National Efficient Price Determination 2024–25. |
| 2024–25 NWAU adjustments | 2024–25 emergency care NWAU adjustments, found in the National Efficient Price Determination 2024–25. |

The variables in Table 11 are required to form the input emergency care dataset.

Table 11: NAPEDC NMDS variables used to calculate the 2024–25 NWAU

|  |
| --- |
| **NAPEDC NMDS variable** |
| State Identifier |
| Establishment identifier |
| Hospital geographical indicator |
| Postcode of patient's usual residence |
| ASGS of patient’s usual residence |
| Indigenous status |
| Date of admission |
| Episode end status |
| Type of visit to emergency care |
| Triage category |
| AECC (Version 1.0) or UDG (Version 1.3). |

# 6. Non-admitted care cost model

## 6.1 Overview

### 6.1.1 Cost unit

The cost unit for non-admitted care is a non-admitted patient service event. This is ‘an interaction between one or more healthcare provider(s) with one non-admitted patient, which must contain therapeutic/clinical content and result in a dated entry in the patient's medical record.’ [[21]](#footnote-22)

### 6.1.2 Scope

The scope of non-admitted care includes service events occurring in outpatient clinics in activity based funding (ABF) hospitals and in the community (by ABF hospitals).

### 6.1.3 Classification

The Tier 2 Non-admitted Care Services Classification Version 9.0 is used to classify   
non-admitted care for the purposes of ABF.

## 6.2 Analysis of costs to derive NWAU for non-admitted care

This section provides an overview of the steps involved in developing the NWAU for non-admitted (outpatient) care. The steps are included below.

### 6.2.1 Adoption of the NHCDC

Historically, the non-admitted cost model relied heavily on the 2012 Ernst and Young Non-admitted and Subacute Care Costing Study (the EY Costing Study) due to the limited quality and stability of NHCDC reporting. With the improvement in reporting and quality of the NHCDC, the cost weights from NEP17 onwards have shifted to adopt the NHCDC.

Table 12 illustrates the shift in hierarchy for non-admitted cost weight selection.

Table 12: Non-admitted cost weight selection hierarchy

| **Cost weight selection hierarchy** | | | |
| --- | --- | --- | --- |
|  | **NEP16** | **NEP17** | **NEP18 to NEP24** |
| Stage 1 | Logical links to acute clinics or other clinics | Logical links to acute clinics | Logical links to acute clinics |
| Stage 2 | Adopt EY Costing Study or other Costing studies | Adopt NHCDC (provided adequate sample and stable across two years) | Adopt NHCDC (provided adequate sample and stable across three years) |
| Stage 3 | Adopt NHCDC | Adopt EY Costing Study or other costing studies | Adopt EY Costing Study or other Costing studies |

Table 13 provides a breakdown for each class by the source data.

Table 13: Non-admitted data source breakdown

| **Source** | **Number of clinics for NEP23** | **Number of clinics for NEP24** |
| --- | --- | --- |
| EY Costing Study | 4 | 3 |
| 2014 Costing Studies (Home Enteral Nutrition, Total Parenteral Nutrition and Home Ventilation Services and PwC Costing Study) | 1 | 0 |
| NHCDC Rounds 23, 24 and 25 | 121 | 124 |
| Harmonised with admitted acute | 2 | 2 |
| Manual treatment | 6 | 7 |
| **Total** | **134** | **136** |

The non-admitted model imposes a three-year time period for the evaluation of stability. The determination of stability in the NHCDC now necessitates the difference in average price between the current data period and previous data collection to be within the 20 per cent threshold, as well as the difference in average price between the last data period and two years ago.

In NEP24, two clinics transitioned from being priced using costing studies, to being priced using the NHCDC. One additional clinic transitioned from being priced using proxy data to being priced using the NHCDC.

Additionally, the Stability Policyrequires that the year-to-year movement in price weights be restricted to a maximum of 20 per cent. In NEP24, this restriction will not apply to three clinics with identified year-to-year price weight movements greater than 20 per cent as these clinics are transitioning from being priced using the Costing Study or proxy data to the NHCDC.

In NEP24, three clinics were stabilised in adherence to the Stability Policy. Table 14 provides the stabilised classes broken down to a series level.

Table 14: Non-admitted stabilised classes by series

| **Series** | **Number of stabilised clinics** |
| --- | --- |
| 20: Medical | 1 |
| 40: Allied health and/or clinic nurse specialist interventions | 2 |

### 6.2.2 Data preparation

Non-admitted patient cost data was received for eight jurisdictions. NHCDC Round 26 (2021–22) included non-admitted data for 289 ABF establishments and 148 Tier 2 classes, compared to 242 ABF establishments and 145 Tier 2 classes in NHCDC Round 25 (2020–21). Similarly to other streams, blood, PBS, and TTR were removed.

In NEP24, the cost weights for some clinics were determined using the 2012 EY Costing Study. The direct costs collected were inflated to 2021–22 in-scope costs using a combination of an historical inflation factor of 1.25 to account for overheads, and the historical NEP indexation rates.

Establishment and class combinations were excluded based on jurisdictional advice and cost ratios being significantly different from the population.

Class specific outlier exclusion rules developed for NEP18 were again included in the NEP24 model. Whole establishments were excluded if their cost ratios across clinics remained consistently high. At the service event level, conservative record level trimming within clinics was undertaken to exclude records with:

* Costs less than $5.
* Events with high-cost thresholds after ranking of events by cost.
* Cost ratios being significantly different from the population.

For class 40.43 *hepatobiliary* a targeted approach was used to remove costs associated with Commonwealth pharmaceutical programs. The cost of new medicines introduced in March 2016 (used in the hepatobiliary clinic) were found to not be accurately excluded in IHACPA’s pharmaceutical claim linking process. Consequently, the direct pharmacy cost bucket values for episodes separated after March 2016 were adjusted to align with the pre-March 2016 average cost of $118 (adjusted for inflation).

For NEP21, the 20 and 40 series COVID-19 responses class prices were pegged to the infectious diseases classes (20.44 and 40.38 respectively), but were priced using NHCDC data for NEP22 onward. The 30 series class is diagnostic and is not priced.

In NEP23, the Tier 2 non-admitted services classification version 8.0 is priced, which adds classes 40.65 *Violence, Abuse & Neglect,* 40.66 *Genetics* as well as 20.58 *Long COVID and* 40.67 *Long COVID*. In the absence of activity or cost data for these classes collected in 2019‑20, 2020‑21 or 2021‑22, the price was determined by combining data from other classes, based on jurisdictional advice. The *Long COVID* clinics 20.58 and 40.67 were pegged to their 20 and 40 series *General Medicine* counterparts 20.05 and 40.53. These approaches continue for NEP24.

In NEP24, the Tier 2 non-admitted services classification version 9.0 is priced, which adds classes 10.22 *Subcutaneous immunoglobulin (SCIg) infusion therapy – home delivered* and 40.68 *Supervised administration of opioid substitution therapy*. In the absence of activity or cost data for these classes collected in 2019–20, 2020–21 or 2021-22, the price was determined by combining data from other classes based on jurisdictional advice.

### 6.2.3 Adjustments

The paediatric adjustment for Tier 2 classes priced using NHCDC only was introduced for NEP20. Adjustments in the non-admitted model are calculated following the admitted acute methodology described in Section 2.2.9.

The application of the paediatric adjustment mirrors the methodology of the acute model as follows:

1. specialist paediatric patients are identified as being less than or equal to 17 years of age, from an establishment identified as delivering specialised paediatric services (listed in **Appendix E** of the National Efficient Price Determination 2024–25 as specialised children’s hospitals).
2. The paediatric adjustment for each Tier 2 class is:
   1. Rounded to the nearest whole per cent.
   2. Capped and floored at 200 per cent and 80 per cent respectively.
   3. Set to one (that is, no adjustment) if the adjustment was within 5 per cent either side of 100 per cent, or the calculated adjustment has changed to be less than or greater than 100 per cent in contrast to the adjustments calculated for NEP23.
3. The cost parameters of each Tier 2 class are then calibrated to ensure that the modelled costs, with the paediatric adjustment applied, are equal to the actual costs of the Tier 2 class.

The adjustments for patient residential area remoteness and Indigenous adjustments are calculated in a single step.

For NEP24, IHACPA has implemented a change to three Tier 2 classes that are multidisciplinary by definition:

* 20.48 Multidisciplinary burns clinic
* 20.56 Multidisciplinary case conference – patient not present
* 40.62 Multidisciplinary case conference – patient not present

The base price of these Tier 2 classes is calculated on cost data reported by jurisdictions, which already reflects the multidisciplinary nature of the care provided under each class. Further application of the non-admitted multidisciplinary clinics (NMC) adjustment would promote overpricing and may distort the model by over-weighting these clinics relative to others.

The NMC value was calculated by averaging across three years of empirical values, in accordance with IHACPA’s Stability Policy, to produce the adopted NMC adjustment.

The Indigenous adjustment is a cost-weighted average value based on all stream data. The patient residential remoteness and patient treatment remoteness values are adopted from the corresponding adjustments in the admitted acute model.

The application of the adjustment parameters mirror the methodology of the acute model as follows:

1. The stabilised NMC adjustment is applied to all multi-disciplinary clinic records excluding the three multidisciplinary clinics listed above, and concurrently, the Indigenous adjustment and patient remoteness adjustment are applied to all Indigenous and/or regional patient records; the class means are then calibrated.
2. The patient treatment remoteness adjustment is applied to all regional patient records and then class means are calibrated.

### 6.2.4 Price weights and NWAU

**Price of a non-admitted ABF activity**

Where:

**APaed** means thepaediatric adjustment

**ANMC** means the non-admitted multi-disciplinary clinic adjustment

**AInd**means the Indigenous adjustment

**ARes**means each or any patient residential remoteness area adjustment

**ATreat**means each or any patient treatment remoteness area adjustment

**NEP** means National Efficient Price 2024–25

**PW** means the price weight for an ABF activity as set out in **Appendix L** of the accompanying National Efficient Price Determination 2024–25

Table 15 outlines the required information in order to apply the above formula.

Table 15: Dataset and tables required for assignment of NWAU to non-admitted patient data

| **Input dataset or table** | **Description** |
| --- | --- |
| ABF NAP NBEDS | Non-admitted patient National Best Endeavours Data Set (ABF NAP NBEDS) |
| 2024–25 NWAU price weight table | 2024–25 non-admitted NWAU price weight table found in the National Efficient Price Determination 2024–25. |
| 2024–25 NWAU adjustments | 2024–25 non-admitted NWAU adjustments found in the National Efficient Price Determination 2024–25. |

Ten variables are required to form the input non-admitted dataset as shown in Table 16.

Table 16: Non-admitted patient ABF DSS variables used to calculate NWAU

| Non-admitted patient ABF DSS variables |
| --- |
| Establishment identifier |
| Indigenous status |
| Date of birth |
| Non-admitted patient service event – service date |
| Multiple healthcare provider indicator (see National Efficient Price Determination 2024–25) |
| Tier 2 non-admitted service class (Version 9.0) |
| Postcode of patient's usual residence |
| ASGS of patient’s usual residence |
| Hospital geographical indicator |
| Funding source |

# 7. Conversion to a pricing model

## 7.1 Overview

The 2024–25 national pricing model is the twelfth annual pricing model that IHACPA has produced. Each pricing model comprises an NEP, price weights and adjustments, and each is based on cost and activity data from three years prior; the 2024–25 pricing model is based on 2021–22 cost and activity data.

The cost and activity data for each of the historical years are used to derive a cost model for that year, with only those costs and activity from ABF establishments being used. The cost model is designed to ensure that the total modelled costs are equalised with the estimated total actual costs across the ABF establishments.


The cost model is made up of cost parameters and adjustments, including the paediatric adjustment, Indigenous adjustment, remoteness area adjustment, COVID-19 treatment adjustment and intensive care unit adjustment, but it excludes the private patient service adjustment and private patient accommodation adjustment. The latter two adjustments are introduced in the pricing model to remove out-of-scope patient costs associated with private patients (see Section 2.2.3 and 2.2.10).

There are four steps in the transformation of each year’s cost model into its associated pricing model, namely:

1. Identification and exclusion of costs and activity regarded under the NHRA as out-of-scope for the purpose of ABF.
2. Derivation of a reference cost (or standardised mean) used to transform the cost model into a cost weight model.
3. Derivation of an annual indexation rate used to inflate the cost model to a level reflective of the estimated cost of delivering hospital services in the year of the pricing model.
4. Transformation of the cost model to the pricing model using the results of the previous three steps.

The process of transforming the 2021–22 cost model to the 2024–25 national pricing model is illustrated in Figure 6.

**Figure 6: Process of transforming the 2021–22 cost model to the 2024–25 national pricing model**



## 7.2 Identification of out-of-scope costs

The first step in the process of transforming cost model to pricing model involves the identification of costs, such as those associated with programs covered entirely, or in part, by other funding sources (for example, Commonwealth or private health insurance). These are referred to as out-of-scope costs, and can be separated into three groups:

* Group 1 – activity funded by other sources. For example:
  + Private patient episodes in private hospitals.
  + Department of Veterans’ Affairs, defence and compensable episodes.
  + Activity which does not meet the criteria on the General List of In-scope Services (the General List*)*, as defined in the National Efficient Price Determination 2024‑‍25, such as Tier 2 class not listed in Category A or Category B of the General List.
* Group 2 – those proportions of costs associated with private patients that are offset by non-government and Commonwealth revenue.
* Group 3 – costs associated with other Commonwealth programs that are inherent within the cost data such as the Highly Specialised Drugs Program and Pharmacy Reform Agreements. Although 2021–22 data is used to set the price, the updated wholesale mark-up arrangements introduced in 1 January 2020 in the 7th Community Pharmacy Agreement have been accounted for in the source data.

Exclusion of these costs from the cost model is undertaken as follows:

1. Group 1 – costs are excluded by restricting the cost model to in-scope activity.
2. Group 2 – costs are excluded through the implementation of the private patient service adjustment and private patient accommodation adjustment within the pricing model (Section 2.2.10).
3. Group 3 – costs are excluded by matching at the patient level where possible, otherwise by first calculating the costs as a percentage of estimated total costs, and then deflating the cost model by this percentage.

## 7.3 Derivation of a reference cost

The second step in the transformation of cost model to pricing model is the derivation of a reference cost (or a mean standardised to ensure the measure of an NWAU remains constant over time) that is used to convert the cost model into a cost weight model. Put simply, the parameters of the cost model are divided by this reference cost, converting the parameters to cost weights.

A separate reference cost is derived for each year’s cost model based on the modelled costs of admitted acute activity in-scope for ABF. In particular, this activity excludes the Group 1 out-of-scope costs discussed in Section 7.2.

The 2009–10 reference cost associated with IHACPA’s first national pricing model is defined as the mean model cost taken across all 2009–10 admitted acute activity in-scope for ABF. This mean model cost is $4,260.

From 2010–11 onward, the reference cost is defined so that change in the reference cost over time reflects change in unit costs, excluding any influence of underlying changes in activity profiles between years (that is, casemix change). So, the 2010–11 reference cost is defined so that the change from the 2009–10 reference cost represents change in unit costs of an NWAU between the 2009–10 and 2010–11 cost models, excluding the effect of any changes in casemix between years. Similarly, the 2020–21 reference cost represents the change in unit cost between the 2019–20 and 2020–21 cost models, excluding the effect of any changes in casemix between years.

To exclude the external effects of casemix change between years, the two cost models are compared by first applying them to a common set of activity, namely 2021–22 admitted acute activity in-scope for ABF.

Once applied to this activity, the resulting pair of mean model costs is calculated, and the change between the two cost models is defined as the change in these two mean values, as shown in Table 17. This is referred to as the standardised change in cost models, with the associated growth referred to as the standardised growth rate. In other words, the growth between the 2020–21 and 2021–22 cost models is standardised against 2020–21 activity.

Table 17 shows the mean model costs of each model based on their application to the 2020–21 ABF activity along with the resulting standardised growth rate.

Table 17: Mean model costs when each cost model is applied to 2021–22 in-scope admitted acute activity data, and resulting standardised growth rate

| **2020–21 cost model** | **2021–22 cost model** | **Standardised growth rate** |
| --- | --- | --- |
| $5,124 | $5,288 | 3.2% |

Finally, the 2021–22 reference cost is defined as the 2020–21 reference cost indexed by the standardised growth rate; that is, the 2021–22 reference cost:

= (2020–21 reference cost) × (standardised growth rate)

= $5,492 × 103.2%

= $5,668

Both 2020–21 and 2021–22 reference costs are given in Table 18.

Table 18: Reference costs for 2020–21 and 2021–22 cost models.

| **2020–21 cost model** | **2021–22 cost model** |
| --- | --- |
| $5,492 | $5,668 |

The conversion of the 2020–21 unadjusted mean model cost given in Table 17 to the 2021–22 reference cost given in Table 18 (that is, $5,492 → $5,668) is referred to as ‘rebasing’.

Figure 7 illustrates this rebasing process in the context of the derivation of the 2021–22 reference cost.

**Figure 7: Derivation of 2021–22 reference cost**

**Year of activity data**

**2020–21**

**2021–22**

**Y**

**$5,668 (**

**C**

**)**

**$5,492 (**

**A**

**)**

**Z**

**X**

**$5,288 (**

**B**

**)**

**A**

**- 2020–21 reference cost**

**X**

**- Crude growth rate to mean cost**

**B**

**- 2021–22 mean cost**

**Y**

**- Standardised growth rate**

**C**

**- 2021–22 reference cost**

**Z**

**- rebasing factor**

There are two intended consequences of the selection of the reference costs:

* The change in reference costs represents change in unit costs excluding the effect of any changes in casemix.
* The 2020–21 and 2021–22 cost weight models give the same total weighted volume when applied to the 2021–22 activity data on which the standardised growth rate is derived.

## 7.4 Indexation

The final step in the transformation of the cost model to pricing model is the indexation of costs to estimate those in the year of the pricing model. Describing the methodology in the context of the 2024–25 pricing model, the objective is to derive an annual indexation rate that is used to inflate the 2021–22 cost model over three years to a level reflective of estimated 2024–25 costs.

To derive this rate, the 2021–22 cost model is applied retrospectively to the five years of patient costed admitted acute activity data[[22]](#footnote-23) prior to 2021–22, and comparisons are made between actual and modelled costs to determine the scaling of the 2021–22 cost model required to equalise each year’s modelled costs and actual costs. The trend of these scaling factors from 2016–17 to 2021–22 is then projected to model the indexation rate for the following three years. As part of this process, normalisation was applied to 2021–22 activity data in line with section 2.2.14.

Figure 8 illustrates the 2021–22 cost model applied to patient costed admitted acute activity data and shows the scaling factors required to ensure the model costs are equalised with actual costs. Since the 2021–22 cost model itself is equalised against 2021–22 actual costs, the scaling factor(s) for 2021–22 is equal to 1 (that is, no scaling is required). Going back through the prior five years of cost data, scaling factors of less than one are required to deflate the modelled costs down to the level of the actual costs. This time series of scaling factors is given by:

,

Denoting the historical total actual costs of the activity by:

,

And denoting the total model costs associated with the 2021–22 cost model applied to each year’s costed activity by:

,

Each year’s scaling factor s*x* is given by:

Multiplying each year’s scaling factor by the final 2021–22 reference cost of $5,668 converts the {*sx*} time series to the time series of costs per weighted separation, where the weighted separations are determined by 2021–22 cost weight model. From the 2021–22 cost model onwards, the effect of the minimum superannuation guarantee is accounted through deflation of the historical total actual costs of activity. For NEP24 this takes the form of deflation of C2021-22 by 0.27 per cent. This is done to ensure changes to the minimum superannuation guarantee are separated from the year-to-year scaling factors. This leads to the elevation of early scaling factors compared to what they would be without this deflation.

This costs per weighted separation series is then used to model an annual scaling factor, denoted ***s***, which would inflate the 2021–22 cost model up to 2024–25 projected actual costs. The indexation rate is then based on this annual scaling factor. This inflation is applied to the raw 2021–22 cost of activity (C2021-22), without deflation of costs to account for changes to the minimum superannuation guarantee.

Figure 8 also illustrates the projected annual scaling factor, ***s****,* together with projected actual and model costs. The 2024–25 projected scaling factor of ***s****3* is pictured alongside projected actual and model costs to illustrate that the 2021–22 cost model would require scaling by ***s****3* to ensure that the resulting ‘***s****3*-scaled 2021–22 cost model’, when applied to 2024–25 patient costed activity, would estimate the actual costs of the activity.

**Figure 8: Illustration of scaling factors required to equalise model and actual costs**

*S*2020–21

*S*2021–22 = 1

S

**S**2

**S**3

2016-17

2020-21

2021-22

2022-23

2023-24

2024-25

Actual costs

*S*2016–17

*S*2020–21

*S*2021–22

S

Model costs derived by applying 2020–21 cost model to costed activity data scaling

Projected

Historical

*S*2016–17

**S**2

**S**3

SX

Scaling factor required to equalise model costs with actual costs

Time series

Projection of time series

A crucial requirement of the scaling factors time series is comparability over time. One way to ensure this occurs is to restrict the data on which the ratios are calculated to the set of establishments for which data is present across all five years (that is, to ensure that all five ratios are calculated across a common set of establishments). While this approach ensures comparability over time, it places significant restrictions on the sample of data.

Instead, an alternate method is used that greatly increases the data sample while maintaining comparability of the ratios over time. This method relies on the fact that any time series of ratios can be equivalently represented as the time series of year-to-year changes in ratios together with a single value of the time series (in this case, the 2020–21 to 2021–22 change in scaling factors of 7.6 per cent). This method only requires that each year-to-year comparison uses a common set of establishments (rather than requiring the establishments to be common across all five years).

The indexation rate relies on the 2021–22 admitted acute cost model only, which is based on AR-DRG Version 11.0.

Table 19 shows the year-to-year changes in scaling factors, calculated by applying the 2021–22 cost model to pairs of consecutive years’ cost data, ensuring a common set of establishments are present in each pairwise comparison.

Table 19: Year-to-year changes in scaling factors

| **2016–17 to 2017–18** | **2017–18 to 2018–19** | **2018–19 to 2019–20** | **2019–20 to 2020–21** | **2020–21 to 2021–22** |
| --- | --- | --- | --- | --- |
| 3.7% | 3.7% | 2.9% | 2.4% | 7.6% |

Table 20 shows the resulting scaling factors time series derived by back-casting the 2021–22 scaling factor of 1.000 using the inverse of the year-to-year changes given in Table 19. Table 20 also shows the equivalent cost per weighted separation time series, with scaling to account for changes to the minimum superannuation guarantee for the 2021–22 cost model onwards. Figure 9 illustrates the cost per weighted separation series graphically.

Table 20: Scaling factors and costs per weighted separation time series derived by applying the 2021–22 cost model and cost weight model to historical patient costed activity data

|  | **2016–17** | **2017–18** | **2018–19** | **2019–20** | **2020–21** | **2021–22** |
| --- | --- | --- | --- | --- | --- | --- |
| **Scaling factor** | 0.8206 | 0.8509 | 0.8821 | 0.9078 | 0.9296 | 1.0000 |
| **Cost per weighted separation** | $4,651 | $4,823 | $5,000 | $5,145 | $5,269 | $5,668 |


The next step in the process of deriving an annual indexation rate is to model a line of best fit against the time series of scaling factors (or equivalently, against costs per weighted separation). This line of best fit is used to estimate the projected annual inflation factor, ***s****,* which was shown in Figure 8.

Given that the annual inflation factor, ***s****,* being modelled is an annual growth rate (that is, ***s***≈ *s*x+1 / *s*x) as opposed to an arithmetic change each year (that is, *s*x+1  *s*x), the line of best fit is taken to have an exponential form. In other words, an exponential form is chosen because exponential functions *A*e*Bx* have the characteristic that their annual growth rate is constant:

The exponential line of best fit is also modelled so that it passes through the 2021–22 observation to ensure that the resulting annual scaling factor applies to the 2021–22 scaling factor of 1.000 (or equivalently, to the 2021–22 reference cost of $5,668).

The time series and associated exponential line of best fit are shown in Figure 9. The two equations displayed in Figure 9 represent the exponential line expressed in terms of the scaling factors time series (with a coefficient of one) and the cost per weighted separation time series.

**Figure 9: Time series of cost per weighted separation with exponential line of best fit. The equation for the line of best fit for the scaling factors time series is included for comparison.**



Note that although the two equations in Figure 9 have different coefficients multiplying the exponential function (that is, one and $5,668), both have precisely the same coefficient inside the exponential function (that is, 0.0414). The two different coefficients multiplying the exponential function represent the estimated scaling factor and cost per weighted separation in ‘year zero’ (that is, x = 0), which is 2021–22. That is, the regression modelled cost ratio for 2021–22 is 1.000 and the modelled cost per weighted separation for 2021–22 is $5,688.

The regression modelled estimates of scaling factors and cost per weighted separation for each of the years from 2016–17 to 2021–22 are given by substituting x = -5…0 into the equations:.

For example, substituting x = 0 into the equations results in the 2021–22 cost ratio and cost per weighted separation:

And,

Finally, the annual scaling factor (that is, ***s*** in Figure 8) is then defined as the annual rate of change associated with the exponential line of best fit, and the indexation rate is the growth rate of this annual scaling factor. The annual rate of change of the exponential line is ***s*** *=* e0.0414, which is equal to 1.042, or 104.2 per cent. Therefore, the indexation rate is 4.2 per cent.

### 7.4.1 Adjustment to account for superannuation guarantee increases

The *Superannuation Guarantee (Administration) Act 1992* section 19(2) legislates increases to the superannuation guarantee from 9.5 per cent to 12 per cent, introduced in 0.5 per cent increments from 2021–22 to 2025–26. As NEP24 is calculated using 2021–22 cost data, and is designed to price 2024–25 activity, this increase in the guarantee is not reflected in the Round 26 NHCDC. The total increase between 2021–22 and 2024–25 is 1.5 per cent.

IHACPA was advised that the hospital workforce is paid superannuation at the guarantee rate in all but two states and territories, meaning that the increase in the guarantee will result in an increase in the total salary package of the hospital workforce in most states and territories. IHACPA therefore calculated a prospective adjustment of 0.81 per cent, to be applied in addition to indexation in the conversion of the reference cost (2021–22) to NEP24 (2024–25).

This adjustment is calculated based on total state and territory labour costs as a proportion of in‑scope costs, identified by NHCDC line items. The proposed adjustment is the national average of the estimated impact of the superannuation increase in each state or territory, weighted by total costs.

## 7.5 Transformation of cost model to pricing model

The final step in the process of developing the pricing models uses the three steps detailed in the previous sections to transform each cost model to the corresponding pricing model.

Each year’s pricing model is designed to reflect estimated total in-scope costs associated with ABF activity in the year of the pricing model. The pricing model is therefore given by the inflated cost model defined in Section 7.4 with those out-of-scope costs defined in Section 7.2 removed. However, the pricing model is represented by the NEP together with price weights and adjustments. This splitting of prices into an NEP component and a price weight component is where the reference cost defined in Section 7.3 plays its role.

To describe the process in the context of the 2024–25 national pricing model, first the 2021–22 cost model is transformed into a cost weight model by dividing it through by the 2021–22 reference cost of $5,668 (see Section 7.3). The 2021–22 cost model is then represented by a reference cost, cost weights and adjustments.

The inflation of the 2021–22 cost model to estimated 2024–25 costs is then undertaken by inflating the 2021–22 reference cost by the annual indexation rate (defined in Section 7.4) and keeping the cost weights and adjustments fixed. For this year, an additional superannuation guarantee adjustment (0.81 per cent) was applied to account for the legislated increase in superannuation from 9.5 per cent to 12 per cent from 2021–22 to 2025–26. The indexed 2021–22 reference cost (including the superannuation guarantee adjustment) is $6,465. This is discussed further in Section 7.4.1.

The indexed 2021–22 reference cost (including the superannuation guarantee adjustment), together with the 2021–22 cost weights and adjustments, then represents the estimated 2024–25 cost model. The following example demonstrates how the process of indexing the reference cost and keeping the cost weights fixed, has the same effect as indexing the entire cost model.

For example, there are two equivalent methods to derive estimated 2024–25 costs for same-day episodes for AR-DRG E42B - bronchoscopy, intermediate complexity.

The 2021–22 same-day cost parameter associated with E42B is $3,899.81. Applying the annual indexation rate of 4.2 per cent to the 2021–22 cost with the superannuation guarantee adjustment, the estimated same-day cost of E42B in 2024–25 is given by:

2024–25 estimated same-day cost of E42B

= (2021–22 estimated cost) × (indexation) × (superannuation guarantee adjustment)

= $3,899.81 × (104.2%) 3 × (100.81%)

= $4,447.85

On the other hand, the same-day cost weight associated with E42B is 0.6880 (= $3,899.81/ $5,668). Applying the annual indexation rate to the 2021–22 reference cost with the superannuation guarantee adjustment, the resulting estimated cost of a same-day episode in E42B in 2024–25 is given by:

2024–25 estimated same-day cost of E42B

= (2021–22 cost weight) × (indexed reference cost) × (superannuation guarantee adjustment)

= 0.6880 × ($5,668 × (104.2%) 3) × (100.81%)

= 0.6880 × $6,465

= $4,447.59

Note there is a minor difference in final result due to rounding of the price weight.

## 7.6 Back-casting for ABF

Back-casting is the process by which the effect of significant changes to the ABF classification systems or costing methodologies are reflected in the pricing model the year prior to implementation, for the purpose of the calculation of the Commonwealth’s funding for each ABF service category.

In accordance with Clauses A34(b) and A41 of the NHRA, the Pricing Authority has applied the methodological changes made in NEP24 to NEP23 to determine the back-cast NEP23 for the purposes of determining Commonwealth growth funding between 2023–24 and 2024–25. The back-cast amount for NEP23 is provided in Chapter 11 of the National Efficient Price Determination 2024–25.

### 7.6.1 Back-casting ABF volume

IHACPA has also estimated the volume impact of methodological changes between NEP23 and NEP24, which can be used for the purpose of estimating movements in volume between NEP23 and NEP24. This is useful for relating NWAU23 activity to NWAU24 targets, and for estimating Commonwealth growth funding prior to actual 2024–25 activity data being available.

The volume multipliers (VM) are calculated for each jurisdiction for each ABF service category stream and are provided in Chapter 11 of the National Efficient Price Determination 2024–25. The back-cast volume multipliers for each jurisdiction (for each ABF product category) are calculated from the most recently reported activity data, namely 2022–23, as:

The volume multipliers can be applied to estimates of an NWAU count for 2024–25 if actual data is not available.

# 8. Block-funded hospitals

## 8.1 General issues

### 8.1.1 Cost unit

The cost unit is a hospital.

### 8.1.2 Scope

Hospitals are in-scope if they have been nominated by a jurisdiction and meet the criteria for block-funded hospitals. The criteria that defines a block-funded hospital is less than or equal to 3,500 total NWAU per annum for rural hospitals and less than or equal to 1,800 admitted patient NWAU per annum for city hospitals.

### 8.1.3 Classification

The cost model for National Efficient Cost Determination 2024–25 (NEC24) comprises of 364 small rural hospitals, four less hospitals compared to NEC23. Of these, 337 were used in the modelling. While 27 hospitals were excluded from modelling due to incomplete data, they continue to have their efficient cost calculated using NEC24 cost model parameters. There are nine major city hospitals, 14 specialist mental health hospitals and one other hospital that are block funded on a separate basis. The initial data preparation of the NEC24 model remains largely unchanged from NEC23, involving the estimation of in-scope activity and expenditure within the admitted, emergency and non-admitted streams.

Similar to the NEC23 cost model, the NEC24 cost model adopts the fixed-plus-variable model with the application of a low-outlier threshold. The low-outlier threshold is used to identify low-outlier establishments which report little activity but demonstrate high cost variability. It is calculated as the activity level (NWAU) corresponding to the mean of the residual (total in-scope expenditure less reference cost x NWAU) divided by double the reference cost. Of the 337 hospitals used for modelling in NEC24, there were 68 low-outlier hospitals, with the remaining 269 hospitals used to develop the cost model. The fixed-plus-variable model includes a:

* Variable component, which is dependent on the hospital’s total activity level and calculated using a dollars-per-NWAU rate based on the corresponding year’s reference cost. For NEC24 this was $5,668 per-NWAU.
* Fixed component, which represents the fixed costs of the hospital where they are not suitably covered through the variable component. This is calculated as the mean of the residual (total in-scope expenditure less reference cost x NWAU) for the hospital cohort of inner regional, outer regional and remote hospitals as well as all low-outlier hospitals with their total NWAU set to zero. The fixed component is dampened based on hospital size: smaller hospitals receive a greater fixed component while the large NEC hospitals, close to the block-funding eligibility threshold of 3,500 NWAU, receive a smaller fixed component.

The modelled cost under the fixed-plus-variable model is the sum of the fixed and variable components. Hospitals identified as low-outliers have their modelled cost set at the fixed component with no dampening or remoteness adjustment applied.

The fixed-plus-variable model continues to recognise two levels of remoteness in the form of:

* remoteness category 1: inner regional, outer regional, remote
* remoteness category 2: very remote.

A remoteness adjustment of 49.4 per cent is applied to the fixed component of very remote hospitals.

## 8.2 Analysis of costs

### 8.2.1 Data preparation

The methodology for NEC24 has been maintained since the data preparation process was updated in NEC17 in line with an update to the national public hospital establishment database (NPHED) in 2014–15. There was another update to the NPHED in 2018–19, which is discussed further in Section 8.2.3. The data preparation process involves:

* Extraction of activity data from the IHACPA ABF DSS for each block-funded hospital and conversion of that data into in-scope NWAUs.
* Extraction of in-scope establishment expenditure data from the NPHED.

The establishment data required to populate the 2021–22 cost model table are:

* Total in-scope NWAU per annum for 2021–22.
* Total in-scope expenditure in 2021–22.

In line with the NEC23 model, the NEC24 model uses a single year of activity data only. This has been done to provide greater model responsiveness and remove the memory effect of a rolling three-year average used in models prior to NEC20.

The eligibility of hospitals for block-funding is determined by ensuring that the latest year’s total NWAU is less than or equal to 3,500 NWAU per annum for rural hospitals, and the admitted patient activity for city hospitals is less than or equal to 1,800 NWAU per annum.

The NWAU activity measure is calculated first and then the best estimate of 2021–22 in-scope expenditure is derived, as set out below. A guide to the process used to prepare data for NEC24 is set out in **Appendix E**: NEC24 data preparation.

### 8.2.2 In-scope activity

Admitted acute and subacute NWAU

Patient-level admitted data was available from approximately 95 per cent of hospitals in the APC stream.

The patient-level admitted data has been fed through the NEP23 NWAU calculator to calculate the in-scope NWAU and public patient equivalent NWAU of all in-scope hospital activity. A slightly modified version of the calculator is used for episodes with an admission date prior to 1 July 2021 in order to determine the NWAU associated to the portion of the episodes occurring in 2021–22. This is discussed further under the ‘work-in-progress episodes’ section below.

For the few hospitals that do not supply patient level admitted data, admitted NWAU is estimated based on the sum of the reported in-scope admitted acute, subacute, other admitted and mental health care expenditure from the NPHED. The number of admitted NWAU is calculated by multiplying the total reported in-scope admitted expenditure by 0.000120.

The admitted multiplier is the parameter estimate from a linear regression of NWAU (using the NEP23 NWAU calculator) versus total reported in-scope admitted expenditure for small hospitals (total public patient equivalent NWAU less than 5,000) that have admitted activity data. Due to known issues in separating admitted and emergency expenditure in Victorian block-funded hospital data, establishments from Victoria were excluded as reference data for this modelling process.

Work-in-progress episodes

The block-funded cost model is used to calculate the expected in-scope cost of a block-funded hospital for a single financial year. The patient-level admitted activity data contains episodes separated in the financial year, in some cases having been admitted up to 20 years prior.

Using the NWAU calculator as it stands would assign 20 years of activity to this single patient, resulting in incomparable cost and activity calculations. On the other hand, there may be episodes admitted during the financial year that have not yet been discharged, and thus do not appear in the activity data. Episodes admitted before the beginning of the financial year or separated after the financial year are referred to as ‘work-in-progress*’* (WIP) patients.

To address this issue, WIP patients who have been separated during the financial year have their total weighted activity reduced so that only NWAU associated to the current financial year are included. To account for WIP patients not yet discharged, each establishment’s total NWAU is scaled up based on state-level ratios calculated. The ratios used for NEC24 are shown in Table 21.

Table 21: State-level admitted WIP ratios

| **State** | **WIP adjustment** |
| --- | --- |
| NSW | 2.2% |
| Vic | 2.7% |
| Qld | 1.6% |
| SA | 2.2% |
| WA | 1.2% |
| Tas | 3.5% |

Emergency care NWAU

Approximately 46 per cent of block-funded hospitals reported emergency activity at the patient level, and 33 per cent reported aggregate presentation information at the UDG level. Also, 16 per cent of block-funded establishments reported basic summary counts and activity estimates. Where available, these data are used to determine NWAU values utilising the NEP23 price weights.

For hospitals that do not supply emergency activity data, emergency NWAU is estimated based on the reported in-scope emergency expenditure from the NPHED. The number of emergency NWAU is calculated by multiplying the total reported in-scope emergency expenditure by 0.000161.

The emergency multiplier is the parameter estimate from a linear regression of NWAU (using the NEP23 NWAU calculator) versus total reported in-scope emergency expenditure for small hospitals (total public patient equivalent NWAU less than 5,000) that have emergency activity data. Due to data quality issues, all establishments from Victoria were excluded as reference data for the modelling process.

Non-admitted NWAU

Approximately 80 per cent of block-funded hospitals reported non-admitted activity at the patient level, and 49 per cent reported aggregate service event information at the class level. Where available, these data are used to determine NWAU values utilising the NEP23 price weights.

For the hospitals that do not supply non-admitted activity, non-admitted NWAU is estimated based on reported in-scope non-admitted expenditure from the NPHED. The number of non-admitted NWAU is calculated by multiplying the total reported in-scope non-admitted expenditure by 0.000089.

The non-admitted multiplier is the parameter estimate from a linear regression of NWAU (using the NEP23 NWAU calculator) versus total in-scope non-admitted expenditure for small hospitals (total public patient equivalent NWAU less than 5,000) that have non-admitted activity data. Due to data quality issues, five establishments from Victoria were excluded as reference data for the modelling process.

### 8.2.3 Out-of-scope expenditure

In 2019–20, the NPHED was updated to introduce six new product streams to capture total recurrent expenditure in areas out-of-scope for the NHRA including:

* admitted acute care (excluding mental health care) (out-of-scope for the NHRA)
* admitted subacute and non-acute care (excluding mental health care) (out-of-scope for the NHRA)
* other admitted care (excluding mental health care) (out-of-scope for the NHRA)
* admitted mental health care (out-of-scope for the NHRA)
* emergency care services (out-of-scope for the NHRA)
* depreciation.

In previous years, where out-of-scope expenditure was not separately identified in the NPHED, an establishment’s in-scope proportion of expenditure was estimated based on the share of in-scope activity data. This aimed to account for any expenditure against services not in-scope under the NHRA. Similarly to NEC23, the NEC24 data preparation process uses the NPHED reported in-scope expenditure at a stream level. This updated in-scope expenditure calculation has been adopted for all jurisdictions except Victoria where the prior methodology of estimating the in-scope amount has been retained.

In addition to the aforementioned out-of-scope product streams, the following NPHED total recurrent expenditure product streams are also treated as out-of-scope in the NEC24 data preparation process:

* direct teaching, training and research
* Commonwealth funded aged care
* other aged care
* non-admitted care (excluding emergency care) (out-of-scope for the NHRA)
* other expenditure (out-of-scope for the NHRA).

### 8.2.4 Calculation of cost parameters

Application of the fixed-plus-variable model and consideration of the low outlier hospitals provided the cost parameters shown in Table 22.

Table 22: Cost parameters of the fixed-plus-variable model and low-outlier establishments

| **Cost parameter** | **Value** |
| --- | --- |
| NEP24 reference cost | $5,668 per NWAU |
| Initial intercept | $1,967,800 |
| Low-outlier threshold | 174 NWAU |
| Low-outlier hospitals | 71 |
| Fixed cost base  (inner regional, outer regional and remote) | $1,992,405 |
| Fixed cost base (very remote) | $2,977,435 |
| Fixed cost dampening rate | 0.029% per NWAU |
| NEC24 very remote adjustment (stabilised) | 49.4% |

The NEC very remote adjustment and dampening only apply to the fixed component and not the variable component or low-outlier hospitals. From NEC22 onwards, the very remote adjustment will be stabilised using a similar method as the NEP models. The stabilised adjustment is calculated as the arithmetic mean of the last three empirically calculated adjustment values.

The dampening rate is calculated such that the fixed component is fully applied at zero NWAU and is completely dampened at 3,500 NWAU, which marks the transition point between block funding and ABF. The purpose of dampening is to gradually reduce the contribution of the fixed component to the overall modelled cost of individual establishments as their activity increases and their variable component, based on the NEP, increases. This is implemented via the use of a multiplier applied to the base fixed component amount:

For NEC24, 364 small rural hospitals have been designated as block funded including the low-outlier hospitals and establishments excluded from the development of the model. These hospitals were categorised by remoteness to determine NEC24.

## 8.3 Calculation of national efficient cost

The efficient cost of a small rural hospital is the sum of the fixed cost component and variable cost component.

### 8.3.1 Calculation of the efficient cost for small rural hospitals

The modelled cost of an in-scope block-funded hospital is given according to:

Where “Total NWAU” is a measure of total in-scope activity by the establishment, and all other terms are as defined in Section 8.2.4. Non-routine hospitals included:

#### Low outliers

* The fixed-plus-variable model is not applied to low-outlier hospitals which have activity below a calculated activity threshold of 174 NWAU.
* The efficient cost of these hospitals is determined as the fixed component with no dampening or very remote adjustment applied.

#### Hospitals with missing data

* Jurisdictional advice was sought on hospitals with missing activity or cost data. Where appropriate, new data received from jurisdictions was incorporated into existing datasets for these hospitals. They are then treated in the same way as hospitals reporting adequate data for the purposes of determining the 2021–22 total cost and NEC24.

In addition to the above, standalone hospitals including specialist psychiatric and major city hospitals are treated separately and are addressed further below.

The efficient cost of an in-scope block-funded hospital is calculated using the formula as above, using cost parameters from Table 22 indexed forward three years (refer to Section 3 of the National Efficient Cost Determination 2024–25).

### 8.3.2 Calculation of the efficient cost of specialist psychiatric, major city and other standalone hospitals

Specialist mental health hospitals are excluded from the model from the outset. These hospitals are assigned model costs based on advice from jurisdictions. Where advice was not received from jurisdictions, reported 2021–22 NPHED data or the final supplementary NEC23 efficient cost has been escalated by the NEC24 adjusted indexation rate to become the NEC24 efficient cost for each of these hospitals. Indexation is described in further detail in Section 8.4.

The 2024–25 efficient cost for the nine major city hospitals, as well as the one other standalone hospital, will be determined separately in a similar way, following consultation with jurisdictions.


## 8.4 Indexation of the 2021–22 model

Due to the three-year time lag in data collection, cost model results for 2021–22 were indexed over three years to give a price model for 2024–25. Figure 10 shows that the raw indexation rate (5.8 per cent) is given by the slope of the exponential line of best-fit of in-scope expenditure for block-funded hospitals across five years. Establishments with data quality issues in 2019–20 or 2020–21 were excluded from the calculation of comparisons using those years.

For NEC24, increases in the minimum superannuation guarantee (refer to Section 7.4.1 for further background information) are reflected in the data resulting in an over-estimation of expenditure growth for affected pairs of years. To account for this, the expenditure of the more recent year of each affected pair is deflated by 0.27 per cent prior to calculation of the cumulative change in expenditure across five years. The raw indexation rate is then adjusted to include an additional 0.81 per cent to prospectively account for increases in the minimum superannuation guarantee. The adjusted NEC24 indexation rate was calculated using the formula:

The overall 2021–22 model spend was projected to 2024–25 using the annual indexation factor of 6.1 per cent per annum, as specified in the National Efficient Cost Determination 2024–25.

**Figure 10: Raw NEC24 Indexation**

****

## 8.5 Back-casting for block-funded hospitals

In accordance with the guiding principles of the NEC cost model, the Pricing Authority has applied the methodological changes made in NEC24 to NEC23 to determine the back-cast NEC23 for the purposes of determining Commonwealth growth funding between 2023–24 and 2024–25. The back-cast multiplier for NEC23 is provided in Chapter 8 of the National Efficient Cost Determination 2024–25.

A back-cast NEC23 is calculated to estimate growth between 2023–24 and 2024–25. The back‑cast NEC23 is calculated by taking the in-scope cost for 2021–22 and indexing it forward two years based on the latest indexation methodology.

# Appendices

[Appendix A: Reference tables 66](#_Toc128649636)

[Appendix B: Application of NWAU variables 68](#_Toc128649637)

[Appendix C: Summary of input data 82](#_Toc128649638)

[Appendix D: List of AR-DRGs adopting the L1.5 H1.5 methodology 84](#_Toc128649639)

[Appendix E: NEC24 data preparation 85](#_Toc128649640)

## Appendix A: Reference tables

**Table 23: Sections of the NEP24 and NEC24 Determinations**

| **Component** | **Section of Determination** |
| --- | --- |
| **National efficient price** | **Chapter 2** |
| **Admitted acute services – NEP24** |  |
| AR-DRG inlier bounds, flags for designated same-day payment AR-DRG and unbundled ICU AR-DRG, national weighted activity unit weights for same-day payment AR-DRGs, short-stay outliers (base and per diem), inliers, long-stay outliers (per diem), intensive care unit rates per hour | **Appendix H** |
| Adjustments to price weights | **Chapter 6** |
| List of radiotherapy codes | **Appendix B** |
| List of dialysis codes | **Appendix C** |
| Specified intensive care units | **Appendix D** |
| Specialised children's hospitals | **Appendix E** |
| Private patient adjustments | **Appendix F** |
| Provisional weights for very long-stay patients | **Appendix G** |
| Funding adjustments for hospital acquired complications | **Appendix N** |
| Risk adjustment factors for avoidable hospital readmissions | **Appendix O** |
| List of COVID-19 treatment adjustment AR-DRGs | **Appendix P** |
| Definition of an eligible ICU or paediatric ICU | **Glossary** |
| **Emergency department services – NEP24** |  |
| AECC Version 1.0 weights | **Appendix L** |
| UDG Version 1.3 classification weights | **Appendix M** |
| Emergency care in-scope for ABF | **Online Glossary** |
| Definitions of emergency care role levels | **Online Glossary** |
| **Non-admitted services – NEP24** |  |
| Tier 2 Non-Admitted Services Classification Version 9.0 weights, paediatric adjustments | **Appendix K** |
| Definition of Tier 2 list of non-admitted services classifications Version 9.0 | **Online Glossary** |
| **Subacute and non-acute services – NEP24** |  |
| AN-SNAP Version 5.0 weights | **Appendix I** |
| Definitions of AN-SNAP Version 5.0 | **Online Glossary** |
| **Admitted mental health care services – NEP24** |  |
| AMHCC inlier bounds and NWAU weights | **Appendix J** |
| Adjustments to price weights | **Chapter 6** |
| Specialised children’s hospitals | **Appendix E** |
| Private patient adjustments | **Appendix F** |
| **Block-funded hospital services – NEC24** |  |
| The efficient costs for each block-funded hospital | **Chapter 3** |

Table 24: Summary of classification systems and sources of cost

| **Service stream** | **Classification[[23]](#footnote-24)** | **Cost data** | **Activity data** |
| --- | --- | --- | --- |
| Admitted acute care | Australian Refined Diagnosis Related Groups Version 11.0 | National Hospital Cost Data Collection (NHCDC) Round 26 (2021–22) | Admitted patient care national minimum data set (APC NMDS) |
| Admitted mental health care | Australian Mental Health Care Classification Version 1.0 | NHCDC Round 26 (2021–22) | Activity based funding (ABF): Mental health care National Best Endeavours Data Set (NBEDS)  APC NMDS |
| Emergency care | AECC Version 1.0  Urgency Disposition Groups Version 1.3 | NHCDC Round 26 (2021–22) | Non-admitted patient emergency department care NMDS  and Emergency service care NMDS |
| Non-admitted care | Tier 2 Outpatient Class Definitions Version 9.0 | NHCDC Round 26 (2021–22) | ABF Non-admitted patient (NAP) NBEDS and ABF NAP care aggregate NBEDS |
| Subacute care  (and non-acute) | AN-SNAP Version 5.0  care type | NHCDC Round 26 (2021–22) | APC NMDS and admitted subacute and non-acute hospital care NBEDS |
| Block-funded services | IHACPA-defined size and Australian Statistical Geography Standards location categorisation on total NWAU for hospital | Expenditure data from the national public hospital establishments database  (2021–22 financial year)  NHCDC Round 26 (2021–22) | APC NMDS, NAPEDC NMDS, ABF ES DSS, NPHED, non-admitted patient and aggregate DSS. |

## Appendix B: Application of NWAU variables

Table 25: Acute admitted patients: variable definitions

| **Variable** | **Name** | **Description** | **Definition** |
| --- | --- | --- | --- |
| A0 | \_pat\_covid\_flag | Patient has:  ICD10AM Version 11 diagnoses U071 or U072; or  ICD10AM Version 12 diagnoses U0711, U0712 or U072  Either supplied in the input dataset or derived from the list of supplied diagnosis codes. | 1 if patient had a COVID-19 diagnosis; else 0. |
| A1 | \_pat\_covid\_treat\_flag | Patient has:  AR-DRG as per **Appendix P** of National Efficient Price Determination 2024–25; and  ICD10AM Version 11 diagnoses U071 (unless also B34.2) or U072 (unless also B34.2); or  ICD10AM Version 12 diagnoses U0712 or U072  Either supplied in the input dataset or derived from the list of supplied diagnosis codes. | 1 if patient meets criteria; else 0. |
| A2 | \_pat\_radiotherapy\_flag | Radiotherapy eligible separation. Either supplied in the input dataset or derived from the list of supplied procedure codes. | 1 if patient had radiotherapy related treatment procedure; else 0. |
| A3 | \_pat\_dialysis\_flag | Dialysis eligible separation. Either supplied in the input dataset or derived from the list of supplied procedure codes. | 1 if patient had a dialysis procedure and is not in AR‑DRG L61Z or L68Z; else 0. |
| A4 | \_est\_eligible\_paed\_flag | Paediatric adjustment eligible establishment, derived from ICU paediatric eligibility table | 1 if establishment is designated as eligible for paediatric adjustment; else 0. |
| A5 | \_est\_eligible\_icu\_flag | ICU rate adjustment eligible establishment, derived from ICU and paediatric eligibility table | 1 if establishment is designated as eligible for ICU rate adjustment; else 0. |
| A6 | \_pat\_remoteness | Patient residential remoteness area | 2021 ASGS remoteness area category of the patient location taken from the episode's geographical information in ranked order of preference: SA2, postcode or the hospital geographical indicator variable where:  0 = major city  1 = inner regional  2 = outer regional  3 = remote  4 = very remote. |
| A7 | \_treat\_remoteness | Patient treatment remoteness area | 2021 ASGS remoteness area category of the patient treatment location taken from the hospitals geographic location information, where: 0 = major city  1 = inner regional  2 = outer regional  3 = remote  4 = very remote. |
| A8 | \_pat\_acute\_flag | Acute patient flag | 1 if (care type = 1) or (care type = 7 and number of qualified days for newborns > 0); else 0. |
| A9 | \_pat\_los | Length of stay | Max (1, (date of separation) - (date of admission) - (total leave days)) if care type = 1; else total qualified days if care type = 7. |
| A10 | \_pat\_sameday\_flag | Same-day flag | 1 if date of admission = date of separation; else 0. |
| A11 | \_pat\_age\_years | Age at admission (in years) | Total whole years from date of birth to date of admission. |
| A12 | \_pat\_eligible\_paed\_flag | Paediatric adjustment eligible patient | 1 if (\_pat\_age\_years between 0 and 17) and (est\_eligible\_paed\_flag=1); else 0. |
| A13 | \_pat\_ind\_flag | Indigenous patient flag | 1 if patient Indigenous status = 1, 2 or 3; else 0. |
| A14 | \_pat\_private\_flag | Private patient flag | 1 if funding source = 9 or 13 for 2012-13 data and later.[[24]](#footnote-25) |
| A15 | \_pat\_public\_flag | Public patient flag | 1 if funding source = 1, 2 or 8 for 2012-13 data and later.[[25]](#footnote-26) |
| A16 | drg\_samedaylist\_flag | Same-day price list flag | 1 if same-day price list variable from joined NWAU AR-DRG price weight table equals ‘Yes’; else 0. |
| A17 | drg\_bundled\_icu\_flag | Bundled ICU flag | 1 if bundled ICU variable from joined NWAU AR-DRG price weight table equals ‘Yes’; else 0. |
| A18 | drg\_inlier\_lb | Inlier lower bound | Inlier lower bound from NWAU AR-DRG price weight table. |
| A19 | drg\_inlier\_ub | Inlier upper bound | Inlier upper bound from NWAU AR-DRG price weight table. |
| A20 | drg\_pw\_sd | Same-day price weight | Same-day price weight from joined NWAU AR-DRG price weight table if not missing; else 0. |
| A21 | drg\_pw\_sso\_base | Short-stay outlier base price weight | Short-stay outlier base price weight from joined NWAU AR-DRG price weight table if not missing; else 0. |
| A22 | drg\_pw\_sso\_perdiem | Short-stay outlier per diem price weight | Short-stay outlier per diem price weight from joined NWAU AR-DRG price weight table if not missing; else 0. |
| A23 | drg\_pw\_inlier | Inlier price weight | Inlier price weight from joined NWAU AR-DRG price weight table. |
| A24 | drg\_pw\_lso\_perdiem | Long-stay outlier per diem price weight | Long-stay outlier per diem price weight from joined NWAU AR-DRG price weight table if not missing; else 0. |
| A25 | drg\_adj\_paed | Paediatric adjustment | Paediatric adjustment from joined NWAU AR-DRG price weight table. |
| A26-33 | drg\_adj\_privpat\_serv*\_JUR* | Private patient service adjustment | Jurisdiction specific private patient service adjustment from joined NWAU AR-DRG price weight table. |
| A34 | \_drg\_inscope\_flag | DRG in-scope flag | 1 if DRG is in-scope; else 0. |
| A35 | adj\_indigenous | See definition | Indigenous adjustment. |
| A36 | adj\_remoteness | See definition | Remoteness adjustment. |
| A37 | adj\_treat\_remoteness | See definition | Patient treatment remoteness adjustment. |
| A38 | adj\_radiotherapy | See definition | Radiotherapy adjustment. |
| A39 | adj\_dialysis | See definition | Dialysis adjustment. |
| A40 | adj\_covid | See definition | COVID-19 treatment adjustment |
| A41 | state\_adj\_privpat\_accomm\_sd | See definition | Private patient accommodation adjustment: same-day rate (state-specific adjustment). |
| A42 | state\_adj\_privpat\_accomm\_on | See definition | Private patient accommodation adjustment: overnight per diem rate (state-specific adjustment). |
| A43 | error\_code | See definition | A brief description of errors, if any, which have occurred in the process of calculating the NWAU of an episode of care. |
| A44 | \_pat\_eligible\_icu\_hours | Whole eligible hours spent in ICU | Total whole hours spent in intensive care (including below level 3 ICU if \_pat\_covid\_flag = 1) unit if hours are greater than or equal to 1; else 0, for unbundled DRGs and eligible establishments |
| A45 | \_pat\_los\_icu\_removed | See definition | Patient length of stay with ICU hours removed |
| A46 | \_pat\_separation\_category | See definition | Patient separation category:  1: Same-day patients  2: Short-stay outlier patients  3: Inlier patients  4: Long-stay outlier patients |
| A47 | \_w01 | DRG by inlier/outlier weight | Based off \_pat\_separation\_category:  1: drg\_pw\_sd  2: drg\_pw\_sso\_base + drg\_pw\_sso\_perdiem \* pat\_los\_icu\_removed  3: drg\_pw\_inlier  4: drg\_pw\_inlier + (pat\_los\_icu\_removed - drg\_inlier\_ub) \* drg\_pw\_lso\_perdiem |
| A48 | \_w02 | Application of the paediatric adjustment | \_w01 \* (1 + \_pat\_eligible\_paed\_flag \* (drg\_adj\_paed)) |
| A49 | \_w03 | Application of the Indigenous, patient residential remoteness, radiotherapy, dialysis and treatment remoteness adjustments. | \_w02 \* (1 + adj\_indigenous + adj\_remoteness + adj\_radiotherapy + adj\_dialysis) \* (1 + adj\_treat\_remoteness) |
| A50 | \_w04 | Application of the COVID‑19 treatment adjustment | \_w03 \* (1 + adj\_covid) |
| A51 | \_adj\_icu | Application of the ICU rate adjustment | \_pat\_eligible\_icu\_hours \* icu\_rate |
| A52 | An110mdc\_ra | MDC v11.0 | Major Diagnostic Category v11.0 |
| A53-A100 | HAC031cXXpYY | HAC Categories and subcategory flags | e.g. HAC031c01p01 = HAC 1.1 = Stage III Pressure Injury |
| A101 | DRG11\_Type | AR-DRG v11.0 Type | Intervention or Medical |
| A102 | agegroup | Age group | Age group in 5 year bands (e.g. Age 20-24) |
| A103 | flag\_ICUHours | See definition. | 1 if episode has ICU Hours; else 0. |
| A104 | flag\_AdmTransfer | See definition. | 1 if episode is has admission mode = ‘transfer’; else 0. |
| A105 | cc\_acute\_myocardial\_function | See definition. | 1 if episode has acute myocardial infarction; else 0. |
| A106 | cc\_congestive\_heart\_failure | See definition. | 1 if episode has congestive heart failure; else 0. |
| A107 | cc\_peripheral\_vascular\_disease | See definition. | 1 if episode has peripheral vascular disease; else 0. |
| A108 | cc\_cerebral\_vascular\_accident | See definition. | 1 if episode has cerebral vascular accident; else 0. |
| A109 | cc\_dementia | See definition. | 1 if episode has dementia; else 0. |
| A110 | cc\_pulmonary\_disease | See definition. | 1 if episode has pulmonary disease; else 0. |
| A111 | cc\_connective\_tissue\_disorder | See definition. | 1 if episode has connective tissue disorder; else 0. |
| A112 | cc\_peptic\_ulcer | See definition. | 1 if episode has peptic ulcer; else 0. |
| A113 | cc\_liver\_disease | See definition. | 1 if episode has liver disease; else 0. |
| A114 | cc\_diabetes | See definition. | 1 if episode has diabetes without complications; else 0. |
| A115 | cc\_diabetes\_complications | See definition. | 1 if episode has diabetes with complications; else 0. |
| A116 | cc\_paraplegia | See definition. | 1 if episode has paraplegia, hemiplegia, or tetraplegia; else 0. |
| A117 | cc\_renal\_disease | See definition. | 1 if episode has renal disease; else 0. |
| A118 | cc\_cancer | See definition. | 1 if episode has primary cancer; else 0. |
| A119 | cc\_metastatic\_cancer | See definition. | 1 if episode has metastatic cancer; else 0. |
| A120 | cc\_severe\_liver\_disease | See definition. | 1 if episode has severe liver disease; else 0. |
| A121 | cc\_HIV | See definition. | 1 if episode has HIV; else 0. |
| A122 | Flag\_instrument\_use | See definition. | 1 if instrument used during delivery; else 0. |
| A123 | Flag\_primiparity | See definition. | 1 if first pregnancy for woman under the age of 16 or over 35; else 0. |
| A124 | Flag\_PPOP | See definition. | 1 if persistent posterior occiput position of fetus; else 0. |
| A125 | Flag\_foetal\_distress | See definition. | 1 if foetal distress during delivery; else 0. |
| A126 | Flag\_emergency | See definition. | 1 if episode has emergency admission urgency; else 0. |
| A127 | Gender | Female indicator of the patient | 2 if female, otherwise 1 |
| A128-A141 | age\_XXg | Age group for HACXX | The age group relevant for risk adjustment of HACXX. |
| A142-A154 | mdc\_XXg | MDC group for HACXX | The MDC group relevant for risk adjustment of HACXX. |
| A155-A168 | HAC\_pointsXX | See definition | Total complexity score for HACXX. |
| A169-A182 | HAC\_risk\_categoryXX | See definition | Complexity group relevant to HACXX. |
| A183-A196 | HAC\_adj\_XX | See definition | Funding adjustment relative to HACXX. |
| A197 | HAC\_adj | Adopted HAC funding adjustment | max(HAC\_adj\_XX) |
| A198 | HAC031\_flag | See definition | 1 if episode has a HAC; else 0. |
| A199 | hacgroup | See definition | HAC group adopted for funding adjustment. |
| A200-A238 | AHR020cXXpYY | AHR categories and subcategory flags | e.g. AHR020c01p01 = AHR 1.1 = Stage III Pressure Injury |
| A239-A250 | AHR\_pointsXX | See definition | Total complexity score for AHRXX. |
| A251-A262 | AHR\_risk\_categoryXX | See definition | Complexity group relevant to AHRXX. |
| A263-A274 | AHR\_adjXX | See definition | Funding adjustment relative to AHRXX. |
| A275 | AHR\_adj | Adopted AHR funding adjustment | max(AHR\_adj\_XX) |
| A276 | AHR020\_flag | See definition | 1 if episode is the index episode for an avoidable readmission; else 0. |
| A277 | w01\_AHR | \_w01 of the readmissions associated with this index episode | See \_w01 [A47] |
| A278 | GWAU24 | Gross Weighted Activity Unit | \_w04 + \_adj\_icu |
| A279 | \_adj\_privpat\_serv | Private patient service adjustment | \_pat\_private\_flag \* drg\_adj\_privapat\_serv\*(\_w01+\_adj\_icu) |
| A280 | \_adj\_privpat\_accom | Private patient accommodation adjustment | \_pat\_private\_flag\*(\_pat\_same-day\_flag\*state\_adj\_private\_accom\_sd+ (1-\_pat\_same-day\_flag)\*\_pat\_los\*state\_adj\_privpat\_accomm\_on) |
| A281 | riskAdjustment\_HAC | NWAU deduction from HAC | if \_pat\_covid\_flag ne 1, \_w01 \* HAC\_adj |
| A282 | riskAdjustment\_AHR | NWAU deduction from readmission index episode | If \_pat\_covid\_flag ne 1, w01\_AHR \* AHR\_adj |
| A283 | NWAU24 | National Weighted Activity Unit | Max(0, GWAU24 - \_adj\_privpat\_serv - \_adj\_privpat\_accom - riskAdjustment\_HAC  - riskAdjustment\_AHR) for only in-scope funding sources, set as necessary in the template. |

Table 26: Admitted mental health care patients: variable definitions

| **Variable** | **Name** | **Description** | **Definition** |
| --- | --- | --- | --- |
| M01 | \_est\_eligible\_paed\_flag | Paediatric adjustment eligible establishment, derived from ICU paediatric eligibility table | 1 if establishment is designated as eligible for paediatric adjustment; else 0. |
| M02 | \_treat\_remoteness | Patient treatment remoteness area | 2021 ASGS remoteness area category of the patient treatment location taken from the hospitals geographic location information, where: 0 = major city  1 = inner regional  2 = outer regional  3 = remote  4 = very remote. |
| M03 | \_pat\_remoteness | Patient residential remoteness area | 2021 ASGS remoteness area category of the patient location taken from the episode's geographical information in ranked order of preference: SA2, postcode or the hospital geographical indicator variable where:  0 = major city  1 = inner regional  2 = outer regional  3 = remote  4 = very remote. |
| M04 | \_pat\_mh\_flag | Mental health care patient flag | 1 if care type = 11, else 0. |
| M05 | \_pat\_gross\_los | Gross length of stay | Max (0, (phase start date) - (phase end date)) |
| M06 | \_pat\_los | Length of stay | Max (0, (phase start date) - (phase end date) - (total leave days in phase)); |
| M07 | \_pat\_ind\_flag | Indigenous patient flag | 1 if patient Indigenous status = 1, 2 or 3; else 0. |
| M08 | \_pat\_sameday\_flag | Same-day flag | 1 if phase start date = phase end date; else 0. |
| M09 | \_pat\_age\_years | Age at phase start (in years) | Total whole years from date of birth to phase start date. |
| M10 | \_pat\_specpaed | Paediatric adjustment eligible patient | 1 if (\_pat\_age\_years between 0 and 17) and (est\_eligible\_paed\_flag=1); else 0. |
| M11 | \_pat\_private\_flag | Private patient flag | 1 if funding source = 9 or 13 for 2012-13 data and later.[[26]](#footnote-27) |
| M12 | \_pat\_public\_flag | Public patient flag | 1 if funding source = 1, 2 or 8 for 2012-13 data and later.[[27]](#footnote-28) |
| M13 | amhcc\_inlier\_lb | Inlier lower bound | Inlier lower bound from NWAU AMHCC price weight table. |
| M14 | amhcc\_inlier\_ub | Inlier upper bound | Inlier upper bound from NWAU AMHCC price weight table. |
| M15 | amhcc\_pw\_sso\_base | Short-stay outlier base price weight | Short-stay outlier base price weight from joined NWAU AMHCC price weight table if not missing; else 0. |
| M16 | amhcc\_pw\_sso\_perdiem | Short-stay outlier per diem price weight | Short-stay outlier per diem price weight from joined NWAU AMHCC price weight table if not missing; else 0. |
| M17 | amhcc\_pw\_inlier | Inlier price weight | Inlier price weight from joined NWAU AMHCC price weight table. |
| M18 | amhcc\_pw\_lso\_perdiem | Long-stay outlier per diem price weight | Long-stay outlier per diem price weight from joined NWAU AMHCC price weight table if not missing; else 0. |
| M19 | priceCat | \_w01 calculation category | 0 for combined AMHCC classes 131, 141; else 1. |
| M20 | amhcc\_adj\_privpat\_serv | Private patient service adjustment | State level private patient service adjustment from joined NWAU AMHCC PPSA table. Determined by the patient’s state and AMHCC. |
| M21 | amhcc\_adj\_privpatNat | National private patient service adjustment | National private patient service adjustment joined from NWAU AMHCC PPSA table. Determined by the patient’s AMHCC. |
| M22 | adj\_indigenous | See definition | Indigenous adjustment. |
| M23 | adj\_remoteness | See definition | Patient residence remoteness adjustment. |
| M24 | adj\_treat\_remoteness | See definition | Patient treatment remoteness adjustment. |
| M25 | adj\_specpaed | See definition | Paediatric adjustment. |
| M26 | state\_adj\_privpat\_accomm\_sd | See definition | Private patient accommodation adjustment: same-day rate (state-specific adjustment). |
| M27 | state\_adj\_privpat\_accomm\_on | See definition | Private patient accommodation adjustment: overnight per diem rate (state-specific adjustment). |
| M28 | error\_code | See definition | Outlines Errors in calculations |
| M29 | \_pat\_separation\_category | See definition | Patient separation category:  2: Short-stay outlier patients  3: Inlier patients  4: Long-stay outlier patients |
| M30 | \_w01 | AMHCC by inlier/outlier weight | For combined AMHCC classes 131 and 141: amhcc\_pw\_sso\_base + \_pat\_los \* amhcc\_lso\_perdiem  Otherwise, based off \_pat\_separation\_category:  2: amhcc\_pw\_sso\_base + amhcc\_pw\_sso\_perdiem \* \_pat\_los  3: amhcc\_pw\_inlier  4: amhcc\_pw\_inlier + (\_pat\_los - amhcc\_inlier\_ub) \* amhcc\_pw\_lso\_perdiem |
| M31 | GWAU24 | Gross Weighted Activity Unit | \_w01 \* (adj\_specpaed) \* (1+adj\_indigenous + adj\_remoteness) \* (1 + adj\_treat\_remoteness) |
| M32 | \_adj\_privpat\_serv | Private patient service adjustment | \_pat\_private\_flag \* amhcc\_adj\_privapat\_serv\*(\_w01) |
| M33 | \_adj\_privpat\_accom | Private patient accommodation adjustment | \_pat\_private\_flag\*(\_pat\_same-day\_flag\*state\_adj\_private\_accom\_sd+ (1-\_pat\_same-day\_flag)\*\_pat\_los\*state\_adj\_privpat\_accomm\_on) |
| M34 | NWAU24 | National Weighted Activity Unit | Max(0, GWAU24 - \_adj\_privpat\_serv - \_adjprivpat\_acomm) for only in-scope funding sources, set as necessary in the template. |

Table 27: Subacute admitted patients: variable definitions

| **Variable** | **Name** | **Description** | **Definition** |
| --- | --- | --- | --- |
| S01 | \_pat\_radiotherapy\_flag | Flag indicating a patient with a radiotherapy procedure code. Either supplied in the input dataset or derived from the list of supplied procedure codes. | 1 if patient had radiotherapy related treatment procedure; else 0. |
| S02 | \_pat\_dialysis\_flag | Flag indicating a patient with dialysis procedure code. Either supplied in the input dataset or derived from the list of supplied procedure codes. | 1 if patient had a dialysis procedure; else 0. |
| S03 | \_treat\_remoteness | Patient treatment remoteness area | 2021 ASGS remoteness area category of the patient treatment location taken from the hospitals geographic location information, where: 0 = major city  1 = inner regional  2 = outer regional  3 = remote  4 = very remote. |
| S04 | \_pat\_remoteness | Patient remoteness area | 2021 ASGS remoteness area category of the patient location taken from the episode's geographical information in ranked order of preference: SA2, postcode, or the hospital geographical indicator variable where:  0 = major city  1 = inner regional  2 = outer regional  3 = remote  4 = very remote. |
| S05 | \_pat\_subacute\_flag | Subacute and non-acute patient flag | 1 if care type = 2, 3, 4, 5, 6 or 88, else 0. |
| S06 | \_pat\_los | Length of stay | If care type = 2, 4, 5, 6 or 88 then:  Max(1,(date of separation) - (date of admission) - (total leave days) ).  If care type = 3 then:  Max(1,(end of phase) - (start of phase) - (total leave days) ). |
| S07 | \_pat\_sameday\_flag | Patient same-day flag | If care type = 2, 4, 5, 6 or 88 then:  1 if date of admission = date of separation; else 0.  If care type = 3 then:  1 if phase start date = phase end date; else 0. |
| S08 | \_pat\_age\_years | Age at admission (in years) | Total whole years from date of birth to date of admission. |
| S09 | \_pat\_ind\_flag | Indigenous patient flag | 1 if patient Indigenous status = 1, 2 or 3; else 0. |
| S10 | \_pat\_private\_flag | Private patient flag | 1 if funding source = 9 or 13 for 2012–13 data and later.[[28]](#footnote-29) |
| S11 | \_pat\_public\_flag | Public patient flag | 1 if funding source = 1, 2, 3 or 8 for 2012–13 data and later.[[29]](#footnote-30) |
| S12 | ansnap\_type | See definition | AN-SNAP class type, as set out in **Appendix I** of the *National Efficient Price Determination 2024–25.* |
| S13 | ansnap\_samedaylist\_flag | Same-day price list flag | 1 if same-day price list variable from joined NWAU AN-SNAP price weight table equals 'Yes'; else 0. |
| S14 | ansnap\_inlier\_lb | Inlier lower bound | Inlier lower bound from NWAU AN-SNAP price weight table. |
| S15 | ansnap\_inlier\_ub | Inlier upper bound | Inlier upper bound from NWAU AN-SNAP price weight table. |
| S16 | ansnap\_pw\_sd | Same-day price weight | If the patient belongs to a same-day AN-SNAP Version 5.0 class then this is the same-day price weight obtained from the NWAU AN-SNAP price weight table. If the patient does not belong to such a class then this value is missing. |
| S17 | ansnap\_pw\_sso\_perdiem | Short-stay outlier per diem price weight | If the patient does not belong to a same-day AN-SNAP Version 5.0 class then this is the short-stay outlier price weight obtained from the NWAU AN-SNAP price weight table. If the patient does belong to such a class then this value is missing. |
| S18 | ansnap\_pw\_inlier | Inlier price weight | If the patient does not belong to a same-day AN-SNAP Version 5.0 class then this is the inlier price weight obtained from the NWAU AN-SNAP price weight table. If the patient does belong to such a class then this value is missing. |
| S19 | ansnap\_pw\_lso\_perdiem | Long-stay outlier per diem price weight | If the patient does not belong to a same-day AN-SNAP Version 5.0 class then this is long-stay outlier price weight obtained from the NWAU AN-SNAP price weight table. If the patient does belong to such a class then this value is missing. |
| S20 | adj\_indigenous | See definition | Indigenous adjustment. |
| S21 | adj\_remoteness | See definition | Remoteness adjustment. |
| S22 | adj\_treat\_remoteness | See definition | Hospital treatment remoteness adjustment. |
| S23 | adj\_radiotherapy | See definition | Radiotherapy adjustment. |
| S24 | adj\_dialysis | See definition | Dialysis adjustment. |
| S25 | caretype\_adj\_privpat\_serv | See definition | Private patient service adjustment (adjustment specific to care type and state). |
| S26 | caretype\_adj\_privpat\_serv\_state | See definition | Private patient service adjustment (adjustment specific to care type and state). |
| S27 | state\_adj\_privpat\_accomm\_sd | See definition | Private patient accommodation adjustment: same-day rate (state-specific adjustment). |
| S28 | state\_adj\_privpat\_accomm\_on | See definition | Private patient accommodation adjustment: overnight per diem rate (state-specific adjustment) |
| S29 | Error\_code | See definition | Outlines errors in calculations |
| S30 | \_pat\_separation\_category | See definition | Patient separation category:  1: Patients belonging to a same day AN-SNAP Version 5.0 class.  2: Short-stay outlier patients  3: Inlier patients  4: Long-stay outlier patients |
| S31 | \_w01 | AN-SNAP inlier/outlier weight | Based off \_pat\_separation\_category:  1: ansnap\_pw\_sd  2: ansnap\_pw\_sso\_perdiem \* pat\_los  3: ansnap\_pw\_inlier  4: ansnap\_pw\_inlier + ( pat\_los - ansnap\_inlier\_ub ) \* ansnap\_pw\_lso\_perdiem |
| S32 | GWAU24 | Gross Weighted Activity Unit, with application of the Indigenous, patient residential remoteness, radiotherapy, dialysis and treatment remoteness adjustments. | \_w01\*(1+adj\_indigenous+adj\_remoteness+adj\_radiotherapy+adj\_dialysis)\*  (1+adj\_treat\_remoteness) |
| S33 | \_adj\_privpat\_serv | Private patient service adjustment | \_pat\_private\_flag \*caretype\_adj\_privpat\_serv\*(\_w01) |
| S34 | \_adj\_privpat\_accom | Private patient accommodation adjustment | \_pat\_private\_flag\*(\_pat\_same-day\_flag\*state\_adj\_private\_accom\_sd+  (1-\_pat\_same-day\_flag)\*\_pat\_los\*state\_adj\_privpat\_accomm\_on) |
| S35 | NWAU24 | National Weighted Activity Unit | Max( 0, GWAU24 - \_adj\_privpat\_serv-\_adj\_privpat\_accomm) for only in-scope funding sources, set as necessary in the template. |

**Table 28: Emergency department: variable definitions**

| **Variable** | **Name** | **Description** | **Definition** |
| --- | --- | --- | --- |
| E01 | \_treat\_remoteness | Patient treatment remoteness area | 2021 ASGS remoteness area category of the patient treatment location taken from the hospitals geographic location information, where: 0 = major city  1 = inner regional  2 = outer regional  3 = remote  4 = very remote. |
| E02 | \_pat\_remoteness | Patient remoteness area | 2021 ASGS remoteness area category of the establishment location taken from patient postcode, ASGS, or the hospital geographical indicator variable, where: 0 = major city  1 = inner regional  2 = outer regional  3 = remote  4 = very remote. |
| E03 | UDG | UDG Version 1.3 | A classification system which may be used to assign a price weight to an emergency department episode of care. This variable may either be supplied by the user or derived from DSS variables: type of visit to emergency care, triage category, and episode end status. See IHACPA website for details. |
| E04 | AECC | AECC Version 1.0 | A classification system which may be used to assign a price weight to an emergency department episode of care. This variable must be supplied by the user. |
| E05 | \_pat\_ind\_flag | Indigenous patient flag | 1 if patient Indigenous status = 1, 2 or 3; else 0. |
| E06 | UDG\_PW | Price weight depending on choice of classification | UDG price weight, taken from the NWAU UDG price weight table. |
| E07 | AECC\_PW | Australian Emergency Care Classification (AECC) Version 1.0 price weight, taken from the NWAU AECC price weight table. |
| E08 | adj\_indigenous | See definition | Indigenous adjustment. |
| E09 | adj\_remoteness | See definition | Patient residence remoteness adjustment. |
| E10 | adj\_treat\_remoteness | See definition | Patient treatment remoteness adjustment. |
| E11 | Error\_Code | See definition | Outlines errors in calculations. |
| E12 | \_w01 | Base predicted | Adopt UDG\_PW, or AECC\_PW depending on classification selection. |
| E13 | GWAU24 | Gross Weighted Activity Unit with application of the Indigenous, patient residential remoteness and treatment remoteness adjustments. | \_w01\*(1+adj\_indigenous+adj\_remoteness)\*(1+adj\_treat\_remoteness). |
| E14 | NWAU24 | National Weighted Activity Unit | GWAU24 for in-scope patients only (that is, non Department of Veterans’ Affairs and compensable patients). |

**Table 29: Non-admitted: variable definitions**

| **Variable** | **Name** | **Description** | **Definition** |
| --- | --- | --- | --- |
| N01 | clinic\_pw | See definition | Tier 2 class price weight, taken from NWAU price weight table. |
| N02 | Tier2\_adj\_paed | Paediatric loading | Tier 2 class paediatric loading, taken from NWAU price weight table. |
| N03 | \_treat\_remoteness | Patient treatment remoteness area | 2021 ASGS remoteness area category of the patient treatment location taken from the hospitals geographic location information, where: 0 = major city  1 = inner regional  2 = outer regional  3 = remote  4 = very remote. |
| N04 | adj\_treat\_remoteness | See definition | Patient treatment remoteness adjustment. |
| N05 | \_pat\_remoteness | Patient residential remoteness area | 2021 ASGS remoteness area category of the patient’s residence as inferred from the following variables, ranked in descending order of preference: SA2, postcode, \_treat\_remoteness. The values of this variable are:  0 = major city  1 = inner regional  2 = outer regional  3 = remote  4 = very remote. |
| N06 | \_est\_eligible\_paed\_flag | Specialist paediatric flag | 1 if the hospital is on the specialist paediatric list, as per the NEP Determination, else 0. |
| N07 | \_pat\_eligible\_paed\_flag | Patient paediatric flag | 1 if \_est\_eligible\_paed\_flag is 1 and patient age < 18, else 0. |
| N08 | \_pat\_ind\_flag | Indigenous patient flag | 1 if patient Indigenous status = 1, 2 or 3; else 0. |
| N09 | adj\_indigenous | See definition | Indigenous adjustment. |
| N10 | adj\_remoteness | See definition | Patient residence remoteness adjustment. |
| N11 | Error\_code | See definition | Outlines errors in calculations. |
| N12 | GWAU24 | Gross Weighted Activity Unit with application of the Indigenous, patient residential remoteness, multidisciplinary clinic and treatment remoteness adjustments. | clinic\_pw\*tier2\_adj\_paed\*(1 + adj\_indigenous + adj\_remoteness + adj\_multiprov)\*(1 + adj\_treat\_remoteness)  Where tier2\_adj\_paed only applies when \_pat\_eligible\_paed\_flag = 1, and adj\_multiprov only applies when event has multiprovider indicator. |
| N13 | NWAU24 | National Weighted Activity Unit | GWAU24 for in-scope funding sources set as necessary in the template. |

## 

## Appendix C: Summary of input data

Table 30: Summary of 2020–21 and 2021–22 patient-costed NHCDC data (Hospitals used for cost modelling)

|  | **Establishments** | | | **Activity (Separations/episodes)\*** | | | **Total reported in‑scope cost** | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 2020–21 | 2021–22 | % Change | 2020–21 | 2021–22 | % Change | 2020–21 | 2021–22 | % Change |
| Admitted acute | 249 | 255 | 2.4% | 6.3M | 6.0M | -3.8% | $32.4B | $34.5B | 6.5% |
| Admitted mental health | 151 | 146 | -3.3% | 110.8K | 104.2K | -6.0% | $2.1B | $2.4B | 13.4% |
| Emergency | 194 | 199 | 2.6% | 8.1M | 8.0M | -0.9% | $6.2B | $7.0B | 11.7% |
| Non-admitted | 242 | 289 | 19.4% | 28.2M | 30.8M | 8.9% | $9.4B | $10.1B | 7.8% |
| Subacute | 244 | 250 | 2.5% | 171.2K | 163.6K | -4.4% | $3.0B | $3.1B | 4.6% |

Note: Only the NHCDC activity is used in the non-admitted cost model.

Table 31: Summary of 2020–21 and 2021–22 population data (Hospitals used for cost modelling)

|  | **Establishments** | | | **Activity (separations/episodes)\*** | | |
| --- | --- | --- | --- | --- | --- | --- |
|  | 2020–21 | 2021–22 | % Change | 2020–21 | 2021–22 | % Change |
| Admitted acute | 270 | 272 | 0.7% | 6.4M | 6.3M | -2.2% |
| Admitted mental health | 191 | 185 | -3.1% | 155.2K | 148.5K | -4.3% |
| Emergency | 204 | 209 | 2.5% | 8.7M | 8.6M | -0.8% |
| Non-admitted |  |  |  |  |  |  |
| Subacute | 257 | 264 | 2.7% | 186.1K | 189.7K | 1.9% |

Table 32: Costed (NHCDC) sample as proportion of total population

|  | **Establishments** | | **Activity (separations)** | |
| --- | --- | --- | --- | --- |
| 2020–21 | 2021–22 | 2020–21 | 2021–22 |
| Admitted acute | 92.2% | 93.8% | 97.8% | 96.1% |
| Admitted mental health | 79.1% | 78.9% | 71.4% | 70.2% |
| Emergency | 95.1% | 95.2% | 93.1% | 93.0% |
| Non-admitted |  |  |  |  |
| Subacute | 93.4% | 92.4% | 77.8% | 77.6% |

Note: Only the NHCDC activity is used in the non-admitted cost model.


## Appendix D: List of AR-DRGs adopting the L1.5 H1.5 methodology


Table 33: List of AR-DRGs adopting the L1.5 H1.5 methodology

| **AR-DRG** | **Description** |
| --- | --- |
| E60B | Cystic Fibrosis, Minor Complexity |
| E76A | Respiratory Tuberculosis, Major Complexity |
| F13A | Amputation, Upper Limb and Toe, for Circulatory Disorders, Major Complexity |
| F61A | Infective Endocarditis, Major Complexity |
| I02A | Microvascular Tissue Transfers or Skin Grafts, Excluding Hand, Major Complexity |
| I07Z | Amputation |
| I12A | Misc Musculoskeletal Procs for Infect/Inflam of Bone/Joint, Major Complexity |
| I31A | Revision of Hip Replacement, Major Complexity |
| P03A | Neonate, Admission Weight 1000-1499g with Significant GI or Ventilation >= 96 Hours, Major Complexity |
| P04A | Neonate, Admission Weight 1500-1999g with Significant GI or Ventilation >= 96 Hours, Major Complexity |
| P05A | Neonate, Admission Weight 2000-2499g with Significant GI or Ventilation >= 96 Hours, Major Complexity |
| P05B | Neonate, Admission Weight 2000-2499g with Significant GI or Ventilation >= 96 Hours, Minor Complexity |
| P06A | Neonate, Admission Weight >= 2500g with Significant GI or Ventilation >= 96 Hours, Major Complexity |
| P06B | Neonate, Admission Weight >= 2500g with Significant GI or Ventilation >= 96 Hours, Minor Complexity |
| P66A | Neonate, Admission Weight 2000-2499g without Significant GI or Ventilation >= 96 Hours, Extreme Complexity |
| T01A | Infectious and Parasitic Diseases with GIs, Major Complexity |
| U62A | Paranoia and Acute Psychotic Disorders, Major Complexity |
| U66A | Eating and Obsessive-Compulsive Disorders, Major Complexity |
| W04A | Multiple Significant Trauma with Other GIs, Major Complexity |
| Y01Z | Ventilation >= 96 Hours or Tracheostomy for Burns or GI for Severe Full Thickness Burns |
| Y02A | Skin Grafts for Other Burns, Major Complexity |

## Appendix E: NEC24 data preparation

Figure 11: National Efficient Cost 2024–25 data preparation





Independent Health and Aged Care Pricing Authority

Level 12, 1 Oxford Street  
Sydney NSW 2000

Phone 02 8215 1100  
Email [enquiries.ihacpa@ihacpa.gov.au](mailto:enquiries.ihacpa@ihacpa.gov.au)  
Twitter [@IHACPAnews](https://twitter.com/IHACPA)

[www.ihacpa.gov.au](http://www.ihacpa.gov.au/)

1. See Glossary Item Newborn qualification status (METeOR identifier: 327254) [↑](#footnote-ref-2)
2. For a list of block funded hospitals see **Appendices A** to **D** of the National Efficient Cost Determination 2024–25 [↑](#footnote-ref-3)
3. See data element Hospital service – care type, code (METeOR identifier 711010) [↑](#footnote-ref-4)
4. See data element Indigenous status (METeOR identifier: 602543). [↑](#footnote-ref-5)
5. Remoteness areas are defined in the Australian Standard Geographic Standard (ASGS),which is maintained by the Australian Bureau of Statistics (see: [www.abs.gov.au](http://www.abs.gov.au/websitedbs/D3310114.nsf/home/remoteness+structure)). The 2021 ASGS remoteness area classification was used to classify patients’ place of residence and locality of hospitals. [↑](#footnote-ref-6)
6. For activity data before 2012–13 see data element ‘Principal source of funding (funding source for hospital patient)(METeOR identifier: 339080), values: 01 Australian Health Care Agreements; 02 Private health insurance; 10 Other hospital or public authority (contracted care); 11 Reciprocal health care agreements (with other countries); 12 Other. [↑](#footnote-ref-7)
7. Data Element Concept Episode of care—source of funding(METeOR identifier: 472038) [↑](#footnote-ref-8)
8. See object class Mental health phase of care (METeOR identifier: 730867). [↑](#footnote-ref-9)
9. See data element Mental health phase of care start date (METeOR identifier 575257). [↑](#footnote-ref-10)
10. See data element Mental health phase of care end date (METeOR identifier 575251). [↑](#footnote-ref-11)
11. See glossary item Admission (METeOR identifier: 327206). [↑](#footnote-ref-12)
12. IHACPA ABF MHC Specifications 2018–19 Version 1.0 [↑](#footnote-ref-13)
13. See data element Hospital service – care type (METeOR identifier 711010) [↑](#footnote-ref-14)
14. For admitted mental health, work in progress records start prior to 1 July 2020. [↑](#footnote-ref-15)
15. L1.5H1.5 refers to the trimming method in which the low trim point is the average length of stay (ALOS) divided by 1.5, and the high trim point is 1.5 times the ALOS. [↑](#footnote-ref-16)
16. Data Element Concept Episode of care—source of funding(METeOR identifier: 472038) [↑](#footnote-ref-17)
17. See object class ‘episode of admitted patient care’ (METeOR identifier: 268956). [↑](#footnote-ref-18)
18. Ibid. [↑](#footnote-ref-19)
19. See glossary item ‘admission’ (METeOR identifier: 327206). [↑](#footnote-ref-20)
20. See Emergency department stay – presentation date, DDMMYYYY (METeOR identifier: 684848). [↑](#footnote-ref-21)
21. See object class Non-admitted patient service event (METeOR identifier: 652089). [↑](#footnote-ref-22)
22. That is, activity from patient costed sites within the National Hospital Cost Data Collection. [↑](#footnote-ref-23)
23. Details of each of the classifications are available from:

    https://www.IHACPA.gov.au/health-care/data/data-specifications/abf-data-request-specifications-2021-22 [↑](#footnote-ref-24)
24. Or 1 if funding source = 2 or 3 for 2011–12 data or earlier. [↑](#footnote-ref-25)
25. Or 1 if funding source = 1, 10 or 11 for 2011–12 data or earlier. [↑](#footnote-ref-26)
26. Or 1 if funding source = 2 or 3 for 2011–12 data or earlier. [↑](#footnote-ref-27)
27. Or 1 if funding source = 1, 10 or 11 for 2011–12 data or earlier. [↑](#footnote-ref-28)
28. Or 1 if funding source = 2 or 3 for 2011–12 data or earlier. [↑](#footnote-ref-29)
29. Or 1 if funding source = 1, 10 or 11 for 2011–12 data or earlier. [↑](#footnote-ref-30)